var title_f5_14_5344="Cryptococcal cellulitis";
var content_f5_14_5344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcal cellulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This renal transplant recipient developed cellulitis over the ankle due to Cryptococcus neoformans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5344=[""].join("\n");
var outline_f5_14_5344=null;
var title_f5_14_5345="Normal tympanic membrane";
var content_f5_14_5345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Normal tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal left tympanic membrane with pearly gray color.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5345=[""].join("\n");
var outline_f5_14_5345=null;
var title_f5_14_5346="Patient information: Parotitis (The Basics)";
var content_f5_14_5346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17041\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/7/33919\">",
"         Parotid gland",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Parotitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/parotitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H200101892\">",
"      <span class=\"h1\">",
"       What is parotitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Parotitis is the term doctors use when the parotid gland gets inflamed or infected. The parotid gland makes saliva. It is located under the skin in front of the ear and above the jaw (",
"      <a class=\"graphic graphic_figure graphicRef63697 \" href=\"UTD.htm?33/7/33919\">",
"       figure 1",
"      </a>",
"      ). Saliva from the parotid gland flows into the mouth through a thin tube called the &ldquo;parotid duct.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101948\">",
"      <span class=\"h1\">",
"       What causes parotitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different viruses and bacteria can cause parotitis.",
"     </p>",
"     <p>",
"      Some people have a higher chance of getting parotitis. People have a higher chance of getting parotitis if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They are dehydrated. This means their body has lost too much water.",
"       </li>",
"       <li>",
"        They just had surgery.",
"       </li>",
"       <li>",
"        They have a blockage in their parotid gland or duct. A blockage can be caused by cancer or a small hard substance called a &ldquo;stone&rdquo; that forms on its own.",
"       </li>",
"       <li>",
"        They take a medicine that causes them to make less saliva.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101899\">",
"      <span class=\"h1\">",
"       What are the symptoms of parotitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Parotitis causes swelling in the area around the parotid gland.",
"     </p>",
"     <p>",
"      If the parotitis is caused by bacteria, people usually have other symptoms, too. That&rsquo;s because the bacteria make pus that collects in or around the parotid gland. This can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain and redness (along with the swelling) in the area around the parotid gland",
"       </li>",
"       <li>",
"        Fever or chills",
"       </li>",
"       <li>",
"        Trouble opening the mouth or swallowing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101906\">",
"      <span class=\"h1\">",
"       Should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Call your doctor or nurse if you have the symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101913\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will ask about your symptoms and do an exam. He or she might also do tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An imaging test &ndash; Imaging tests create pictures of the inside of the body. Your doctor might do an ultrasound, CT scan, or MRI scan.",
"       </li>",
"       <li>",
"        Lab tests &ndash; If you have a collection of pus, your doctor can take a small sample of the pus. He or she can send it to the lab to find out what kind of bacteria is causing your infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101920\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help your symptoms, your doctor or nurse might recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put heat on the swollen area. Wet a clean wash cloth with warm water and put it on the area. When the wash cloth cools, reheat it with warm water and put it back on. Repeat these steps for 10 to 15 minutes every few hours.",
"       </li>",
"       <li>",
"        Drink lots of fluids.",
"       </li>",
"       <li>",
"        Gently massage the swollen area.",
"       </li>",
"       <li>",
"        Suck on sour or lemon-flavored hard candy.",
"       </li>",
"       <li>",
"        Take an over-the-counter medicine to treat your pain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101927\">",
"      <span class=\"h1\">",
"       What other treatment might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Other treatment depends on the germs causing the infection and how serious your infection is. Parotitis caused by a virus doesn&rsquo;t usually need other treatment.",
"     </p>",
"     <p>",
"      Parotitis caused by bacteria is treated with antibiotic medicines. These medicines go into your vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      If you have severe pain, your doctor can prescribe a strong pain medicine.",
"     </p>",
"     <p>",
"      If you have a collection of pus that doesn&rsquo;t get better with antibiotics, your doctor might do surgery to drain the pus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200101934\">",
"      <span class=\"h1\">",
"       Can parotitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, in some cases. A vaccine called the &ldquo;MMR&rdquo; vaccine can help prevent parotitis. (Vaccines are treatments that prevent serious infections.) The MMR vaccine prevents an infection called &ldquo;mumps,&rdquo; which is a virus that can cause parotitis.",
"     </p>",
"     <p>",
"      Doctors recommend that all children get the MMR vaccine as part of their routine childhood vaccines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H200102005\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/14/5346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17041 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5346=[""].join("\n");
var outline_f5_14_5346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101892\">",
"      What is parotitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101948\">",
"      What causes parotitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101899\">",
"      What are the symptoms of parotitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101906\">",
"      Should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101913\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101920\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101927\">",
"      What other treatment might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200101934\">",
"      Can parotitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200102005\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/7/33919\">",
"      Parotid gland",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5347="Ovulation aromatase inhibitors";
var content_f5_14_5347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aromatase inhibitor treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clomiphene Citrate: (Day 5) Administration of clomiphene citrate (CC) from days 3 to 7 results in estrogen receptor (ER) depletion at the level of the pituitary and mediobasal hypothalamus. As a result, estrogen negative feedback centrally is interrupted and FSH secretion increases from the anterior pituitary leading to multiple follicular growth. (Day 10) By the late follicular phase, because of the long tissue retention of CC, there continues to be ER depletion centrally and increased estradiol (E2) secretion from the ovary is not capable of normal negative feedback on FSH. The result is multiple dominant follicle growth and multiple ovulation. Aromatase Inhibitor: (Day 5) Administration of an aromatase inhibitor (AI) from 3 to 7 days results in suppression of ovarian estradiol (E2) secretion and reduction in estrogen negative feedback at the pituitary and mediobasal hypothalamus. Increased FSH secretion from the anterior pituitary results in stimulation of multiple ovarian growth. (Day 10) Later in the follicular phase, the effect of the AI is reduced and E2 levels increase as a result of follicular growth. Because AIs do not affect estrogen receptors (ER) centrally, the increased E2 levels result in normal negative feedback on FSH secretion and follicles less than dominant follicle size undergo atresia, with resultant monofollicular ovulation in most cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5347=[""].join("\n");
var outline_f5_14_5347=null;
var title_f5_14_5348="Overview of hemorrhoids";
var content_f5_14_5348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hemorrhoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5348/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5348/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/14/5348/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoids are normal vascular structures in the anal canal. However, they are often the source of a variety of problems. The cardinal features of hemorrhoidal disease include bleeding, anal pruritus, prolapse, and pain due to thrombosis.",
"   </p>",
"   <p>",
"    Hemorrhoidal disease is a common problem. A large database survey conducted in the United States and England found a prevalence of approximately 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence was equal in both sexes, peaking between the ages of 45 and 65, and declining thereafter. Development of symptoms prior to age 20 was unusual.",
"   </p>",
"   <p>",
"    However, the true prevalence is uncertain since the diagnosis of hemorrhoidal disease tends to be imprecise. Almost any anorectal discomfort is often attributed to symptomatic hemorrhoids.",
"   </p>",
"   <p>",
"    This topic will review the anatomic classification, clinical manifestations, and diagnosis of hemorrhoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoids arise from a plexus (sometimes called a \"cushion\") of dilated arteriovenous channels and connective tissue with the veins arising from the superior and inferior hemorrhoidal veins. They are located in the submucosal layer in the lower rectum and may be external or internal based upon whether they are below or above the dentate line. Both types of hemorrhoids often coexist.",
"   </p>",
"   <p>",
"    Internal hemorrhoids arise from the superior hemorrhoidal cushion. Their three primary locations (left lateral, right anterior, and right posterior) correspond to the end branches of the middle and superior hemorrhoidal veins. The overlying mucosa is rectal, and innervation is visceral.",
"   </p>",
"   <p>",
"    External hemorrhoids arise from the inferior hemorrhoidal plexus and are located beneath the dentate line. They are covered with squamous epithelium, which contains numerous somatic pain receptors. External skin tags are sometimes confused with external hemorrhoids. Perianal skin tags are associated with many conditions such as anal fissures or perianal Crohn's disease. Skin tags may also represent the residual excess skin associated with prior thrombosis of external hemorrhoids, not the hemorrhoids themselves. Hypertrophic, edematous, and tender skin tags should raise suspicion for underlying Crohn's disease, particularly in patients with other clinical features of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal and external hemorrhoids communicate with one another and drain into the internal pudendal veins, and ultimately the inferior vena cava. Hemorrhoids have direct communication with the portal system, and can also exist in close proximity to rectal varices in patients who have portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/2\">",
"     2",
"    </a>",
"    ]. Hemorrhoids are not more common in patients with portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal hemorrhoids are graded according to the degree to which they prolapse from the anal canal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I hemorrhoids are visualized on anoscopy and may bulge into the lumen but do not extend below the dentate line.",
"     </li>",
"     <li>",
"      Grade II hemorrhoids prolapse out of the anal canal with defecation or with straining but reduce spontaneously.",
"     </li>",
"     <li>",
"      Grade III hemorrhoids prolapse out of the anal canal with defecation or straining, and require the patient to reduce them into their normal position.",
"     </li>",
"     <li>",
"      Grade IV hemorrhoids are irreducible and may strangulate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No widely used classification system of external hemorrhoids exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of symptomatic hemorrhoids has been associated with advancing age, diarrhea, pregnancy, pelvic tumors, prolonged sitting, straining, and chronic constipation. The association with chronic constipation, however, was not supported in a large epidemiologic study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of symptomatic internal hemorrhoids is not completely understood, but three predominant theories have been advanced. The first theory posits that, with advancing age or aggravating conditions, the connective tissue which anchors hemorrhoids to the underlying sphincter mechanism deteriorates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/4\">",
"     4",
"    </a>",
"    ]. Eventually, the weakly anchored hemorrhoids begin to bulge, and \"slide\" into the anal canal leading to progressive symptoms.",
"   </p>",
"   <p>",
"    The second theory suggests that symptomatic hemorrhoids arise from hypertrophy or increased tone of the internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. During defecation, the fecal bolus forces the hemorrhoidal plexus against the internal sphincter, which causes them to enlarge and become symptomatic.",
"   </p>",
"   <p>",
"    The third theory attributes the development of symptoms to swelling of the hemorrhoidal cushions. This theory assumes that the anatomic properties of the hemorrhoidal plexus are similar to those of erectile tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/2\">",
"     2",
"    </a>",
"    ]. In support of this hypothesis is the observation that hemorrhoids regress following ligation of the hemorrhoidal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence support or contradict each theory. However, the cause may be different in individual patients or multiple factors may coexist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemorrhoids usually seek treatment for painless bleeding, prolapse, pain associated with a thrombosed hemorrhoid, pruritus, or fecal soilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless bleeding is usually associated with a bowel movement. Bright red blood typically coats the stool at the end of defecation. Blood may also drip into the toilet or stain toilet paper. Chronic blood losses from hemorrhages can be substantial enough to induce iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5348/abstract/8\">",
"     8",
"    </a>",
"    ]. Occasionally, bleeding can be copious and distressing for the patient.",
"   </p>",
"   <p>",
"    Hemorrhoidal bleeding is almost always painless. Thus, bleeding associated with painful defecation should prompt investigation for other causes such as anorectal fissures.",
"   </p>",
"   <p>",
"    Visible rectal or occult bleeding should not be attributed to hemorrhoids until other potential bleeding sites have been excluded by endoscopic testing. Flexible sigmoidoscopy or anoscopy in low-risk younger patients or colonoscopy in most other patients establishes the diagnosis of hemorrhoids, and excludes other causes of bleeding such as colitis, tumors, polyps, or vascular malformations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritation or itching of perianal skin is another common symptom of hemorrhoidal disease. Some patients also complain of mild incontinence or wetness. These symptoms result from a combination of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolapse of internal hemorrhoids may permit leakage of rectal contents (",
"      <a class=\"graphic graphic_picture graphicRef75759 \" href=\"UTD.htm?35/27/36272\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Skin tags associated with external hemorrhoids may be difficult to clean, resulting in prolonged contact of fecal material with the perianal skin and leading to local irritation.",
"     </li>",
"     <li>",
"      Swelling associated with hemorrhoidal irritation may contribute in some patients.",
"     </li>",
"     <li>",
"      Patients with leakage may clean aggressively, irritating the perianum and also allowing contact of fecal material with denuded skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=see_link\">",
"       \"Approach to the patient with anal pruritus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain associated with hemorrhoids may be associated with a palpable \"lump.\" This usually results from thrombosis, which can occur in both internal and external hemorrhoids. Thrombosis of external hemorrhoids may be associated with excruciating pain (",
"    <a class=\"graphic graphic_picture graphicRef72916 \" href=\"UTD.htm?14/30/14831\">",
"     picture 2",
"    </a>",
"    ). The overlying perianal skin is highly innervated and becomes distended and inflamed. The thrombosed external hemorrhoid is an easily visible, purple, elliptical mass extending from the anal to the perianal skin. It is extremely painful to palpation, and a thrombus may be appreciated.",
"   </p>",
"   <p>",
"    Thrombosed internal hemorrhoids may also cause pain, but to a lesser degree than external hemorrhoids. An exception is when internal hemorrhoids strangulate, which most often occurs in grade IV disease. The associated lack of blood supply can lead to gangrene, which is life-threatening if not immediately treated. In such cases, treatment is surgical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a variety of other anorectal disorders may present with a presumed diagnosis of hemorrhoids. Examples include anal fissures, condyloma, rectal prolapse, anal cancer, and Crohn's disease. Thus, these diagnoses should be excluded, particularly if conservative treatment for hemorrhoids has not been successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97316558\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical, minimally invasive, and surgical treatment of hemorrhoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link\">",
"     \"Treatment of hemorrhoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=see_link\">",
"       \"Patient information: Hemorrhoids (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/7/28786?source=see_link\">",
"       \"Patient information: Anal pruritus (anal itching) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"       \"Patient information: Hemorrhoids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoids are normal vascular structures in the anal canal, arising from a channel of arteriovenous connective tissues which drains into the superior and inferior hemorrhoidal veins. They are located in the submucosal layer in the lower rectum and may be external or internal based upon whether they are below or above the dentate line.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Internal hemorrhoids are graded according to the degree to which they prolapse from the anal canal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of symptomatic internal hemorrhoids is not completely understood, but may be due to multiple factors: advancing age or aggravating conditions, causing deterioration of the connective tissue which anchors the hemorrhoids to the underlying sphincter mechanism, hypertrophy or increased tone of the internal anal sphincter,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling of the hemorrhoidal cushions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of hemorrhoidal disease include bleeding, anal pruritus, prolapse, and pain due to thrombosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/1\">",
"      Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology 1990; 98:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/2\">",
"      Thomson WH. The nature of haemorrhoids. Br J Surg 1975; 62:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/3\">",
"      Misra SP, Dwivedi M, Misra V. Prevalence and factors influencing hemorrhoids, anorectal varices, and colopathy in patients with portal hypertension. Endoscopy 1996; 28:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/4\">",
"      Haas PA, Fox TA Jr, Haas GP. The pathogenesis of hemorrhoids. Dis Colon Rectum 1984; 27:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/5\">",
"      Miles WE. Observations upon internal piles. Surg Gynecol Obstet 1919; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/6\">",
"      Arabi Y, Alexander-Williams J, Keighley MR. Anal pressures in hemorrhoids and anal fissure. Am J Surg 1977; 134:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/7\">",
"      Morinaga K, Hasuda K, Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. Am J Gastroenterol 1995; 90:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5348/abstract/8\">",
"      Kluiber RM, Wolff BG. Evaluation of anemia caused by hemorrhoidal bleeding. Dis Colon Rectum 1994; 37:1006.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2541 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5348=[""].join("\n");
var outline_f5_14_5348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97316558\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2541|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/27/36272\" title=\"picture 1\">",
"      Prolapsed internal hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/30/14831\" title=\"picture 2\">",
"      Thrombosed external hemorrhoid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15110?source=related_link\">",
"      Approach to the patient with anal pruritus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/7/28786?source=related_link\">",
"      Patient information: Anal pruritus (anal itching) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=related_link\">",
"      Treatment of hemorrhoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5349="Tinidazole: Drug information";
var content_f5_14_5349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tinidazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4581?source=see_link\">",
"    see \"Tinidazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tindamax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Amebicide;",
"     </li>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antiprotozoal, Nitroimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amebiasis, intestinal:",
"     </b>",
"     Oral: 2 g/day for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amebiasis, liver abscess:",
"     </b>",
"     Oral: 2 g/day for 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial vaginosis:",
"     </b>",
"     2 g/day for 2 days or 1 g/day for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Giardiasis:",
"     </b>",
"     Oral: 2 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Trichomoniasis:",
"     </b>",
"     Oral: 2 g as a single dose; sexual partners should be treated at the same time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urethritis (unlabeled use):",
"     </b>",
"     Oral: 2 g as a single dose with azithromycin (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F228042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amebiasis, intestinal:",
"     </b>",
"     Oral: Children &gt;3 years: 50 mg/kg/day for 3 days (maximum dose: 2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amebiasis, liver abscess:",
"     </b>",
"     Oral: Children &gt;3 years: 50 mg/kg/day for 3-5 days (maximum dose: 2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Giardiasis:",
"     </b>",
"     Oral: Children &gt;3 years: 50 mg/kg as a single dose (maximum dose: 2 g)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjustment not necessary. An additional dose equal to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the  usual dose, should be administered at the end of hemodialysis if tinidazole is administered on a day hemodialysis occurs.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific recommendations are not available; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tindamax&reg;: 250 mg, 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of trichomoniasis caused by",
"     <i>",
"      T. vaginalis",
"     </i>",
"     ; treatment of giardiasis caused by",
"     <i>",
"      G. duodenalis",
"     </i>",
"     (",
"     <i>",
"      G. lamblia",
"     </i>",
"     ); treatment of intestinal amebiasis and amebic liver abscess caused by",
"     <i>",
"      E. histolytica",
"     </i>",
"     ; treatment of bacterial vaginosis caused by",
"     <i>",
"      Bacteroides",
"     </i>",
"     spp,",
"     <i>",
"      Gardnerella vaginalis",
"     </i>",
"     , and",
"     <i>",
"      Prevotella",
"     </i>",
"     spp in nonpregnant females",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue/malaise (1% to 2%), dizziness (&le;1%), headache (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhagia (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Metallic/bitter taste (4% to 6%), nausea (3% to 5%), anorexia (2% to 3%), appetite decreased (&gt;2%), flatulence (&gt;2%), dyspepsia/cramps/epigastric discomfort (1% to 2%), vomiting (1% to 2%), constipation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary:",
"     <i>",
"      Candida",
"     </i>",
"     vaginitis (5%), painful urination (&gt;2%), pelvic pain (&gt;2%), urine abnormality (&gt;2%), vaginal odor (&gt;2%), vulvovaginal discomfort (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urinary tract infection (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (&gt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, coma (rare), confusion (rare), depression (rare), drowsiness, fever, giddiness, insomnia, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, furry tongue (rare), oral candidiasis, salivation, stomatitis, thirst, tongue discoloration, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urine darkened, vaginal discharge increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (transient), neutropenia (transient), thrombocytopenia (reversible; rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, myalgia, peripheral neuropathy (transient, includes numbness and paresthesia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm (rare), dyspnea (rare), pharyngitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Burning sensation,",
"     <i>",
"      Candida",
"     </i>",
"     overgrowth, diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute hypersensitivity reaction (severe), erythema multiforme, Stevens-Johnson syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tinidazole, nitroimidazole derivatives (including metronidazole), or any component of the formulation; pregnancy (1st trimester); breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic:",
"     <b>",
"      [U.S. Boxed Warning]: Carcinogenicity has been observed with another nitroimidazole derivative (metronidazole) in animal studies;",
"     </b>",
"     use should be reserved for approved indications only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Seizures and peripheral neuropathy have been reported with tinidazole and other nitroimidazole derivatives; use with caution in patients with CNS diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), pseudomembranous colitis, and/or vaginal candidiasis. CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Amebiasis: Appropriate use: When used for amebiasis, not indicated for the treatment of asymptomatic cyst passage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Use with caution in patients with current or a history of blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with current or a history of hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &le;3 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F228043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Tinidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: Tinidazole may enhance the adverse/toxic effect of Disulfiram.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F228024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: The manufacturer recommends to avoid all ethanol or any ethanol-containing drugs (may cause disulfiram-like reaction characterized by flushing, headache, nausea, vomiting, sweating or tachycardia) during and for at least 3 days after completion of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Carcinogenicity studies have not been completed with tinidazole; however, metronidazole has a similar chemical structure and has caused carcinogenic effects in rats and mice. Tinidazole crosses the human placenta and enters the fetal circulation. Use of tinidazole is contraindicated during the first trimester of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated (AAP rates \"of concern\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F228014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tinidazole is excreted into breast milk in concentrations similar to those in the maternal serum and can be detected for up to 72 hours after administration. Tinidazole is contraindicated in nursing mothers unless breast-feeding is interrupted during therapy and for 3 days after the last dose.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F228015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. The manufacturer recommends that ethanol be avoided during treatment and for 3 days after therapy is complete.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tindamax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (40): $281.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (20): $281.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tinidazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (40): $203.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (20): $203.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amibiol (CO);",
"     </li>",
"     <li>",
"      Asgin (TW);",
"     </li>",
"     <li>",
"      Dyzole (NZ);",
"     </li>",
"     <li>",
"      Estovit-T (MX);",
"     </li>",
"     <li>",
"      Fasigin (IT, PL);",
"     </li>",
"     <li>",
"      Fasigyn (AR, AT, BE, BG, BR, BZ, CH, CN, CO, CR, EC, GR, GT, HN, IL, IN, MX, NI, NL, PA, PE, PK, PT, RU, SE, SG, SV, TH, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Fasigyne (FR);",
"     </li>",
"     <li>",
"      Induken (MX);",
"     </li>",
"     <li>",
"      Jie Li (CL);",
"     </li>",
"     <li>",
"      Simplotan (AT);",
"     </li>",
"     <li>",
"      Su (TW);",
"     </li>",
"     <li>",
"      Tindol (MY);",
"     </li>",
"     <li>",
"      Tiniba (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Tinidazine (KP);",
"     </li>",
"     <li>",
"      Tricolam (ES);",
"     </li>",
"     <li>",
"      Tricor 500 (PY);",
"     </li>",
"     <li>",
"      Trinigyn (BB, BM, BS, GY, JM, SR, TT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After diffusing into the organism, it is proposed that tinidazole causes cytotoxicity by damaging DNA and preventing further DNA synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 50 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 12%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (primarily); undergoes oxidation, hydroxylation and conjugation; forms a metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (20% to 25%); feces (12%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5349/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5349/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamp KC, Freeman CD, Klutman NE, &ldquo;Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 36(5):353-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5349/abstract-text/10384859/pubmed\" id=\"10384859\" target=\"_blank\">",
"        10384859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li XQ, Bjorkman A, Andersson TB, et al, &ldquo;Identification of Human Cytochrome P(450)s that Metabolise Anti-Parasitic Drugs and Predictions of",
"      <i>",
"       in vivo",
"      </i>",
"      Drug Hepatic Clearance from",
"      <i>",
"       in vitro",
"      </i>",
"      Data,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2003, 59(5-6):429-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5349/abstract-text/12920490/pubmed\" id=\"12920490\" target=\"_blank\">",
"        12920490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10205 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5349=[""].join("\n");
var outline_f5_14_5349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708927\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228029\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228048\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228033\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228042\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062235\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228034\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228035\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228005\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227992\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228007\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228006\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228046\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228011\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227994\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228043\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227999\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228024\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228002\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228013\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228038\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228014\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228015\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422283\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228016\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228010\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4581?source=related_link\">",
"      Tinidazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5350="Salsalate: Drug information";
var content_f5_14_5350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Salsalate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/33/43540?source=see_link\">",
"    see \"Salsalate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11586341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amigesic&reg;;",
"     </li>",
"     <li>",
"      Salflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Salicylate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain, inflammation (arthritis):",
"     </b>",
"     Oral: 3 g/day in 2-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. May require lower dosage.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9614166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of rheumatoid arthritis, osteoarthritis, and related rheumatic disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Salsalate may be confused with sucralfate, sulfaSALAzine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, GI bleeding, GI perforation, GI ulceration, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, liver function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine clearance decreased, nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salsalate or any component of the formulation; asthma, urticaria, or allergic reaction to aspirin or NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of salsalate, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity. Previous nonreaction does not guarantee future safe taking of medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Response to ACE inhibitors, thiazides, or loop diuretics may be impaired with concurrent use of NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; patients should be instructed to contact their healthcare provider if these occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Salsalate peak serum levels may be delayed if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, ginseng (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Due to the known effects of salicylates (closure of ductus arteriosus), use during late pregnancy should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F219950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salsalate is metabolized to salicylic acid which is excreted in breast milk in concentrations equivalent to maternal blood concentrations. An infant may ingest up to 80% per kg body weight as the mother is taking.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Salsalate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $67.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $62.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Disal (KP, TW);",
"     </li>",
"     <li>",
"      Disalcid (BB, BM, BS, BZ, GY, JM, NL, SR, TT);",
"     </li>",
"     <li>",
"      Mono-Getic (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weakly inhibits cyclooxygenase enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees) include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: 3-4 days of continuous dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Complete from small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically hydrolyzed to two moles of salicylic acid (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chapman BJ and Proudfoot AT, &ldquo;Adult Salicylate Poisoning: Deaths and Outcome in Patients With High Plasma Salicylate Concentrations,&rdquo;",
"      <i>",
"       Q J Med",
"      </i>",
"      , 1989, 72(268):699-707.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2602553/pubmed\" id=\"2602553\" target=\"_blank\">",
"        2602553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dugandric RM, Tierney MG, and Dickinson GE, &ldquo;Evaluation of the Done Nomogram in the Management of Acute Salicylate Intoxication,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1989, 18(11):1186-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2817562/pubmed\" id=\"2817562\" target=\"_blank\">",
"        2817562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spontak SF, Hassan FM, and Spadafora MP, &ldquo;Salsalate Intoxication and Ramifications of Utilizing Nonspecific Analytical Methods in Estimating Quantitative Blood Concentrations,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1994, 18(4):229-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/7967546/pubmed\" id=\"7967546\" target=\"_blank\">",
"        7967546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vandenberg SA, Smolinske SC, Spoerke DG, et al, &ldquo;Nonaspirin Salicylates: Conversion Factors for Estimating Aspirin Equivalency,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1989, 31(1):49-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2652876/pubmed\" id=\"2652876\" target=\"_blank\">",
"        2652876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vertrees JE, McWilliams BC, and Kelly HW, &ldquo;Repeated Oral Administration for Treating Aspirin Overdose in Young Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 85(4):594-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/2314974/pubmed\" id=\"2314974\" target=\"_blank\">",
"        2314974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weissmann G, &ldquo;Aspirin,&rdquo;",
"      <i>",
"       Sci Am",
"      </i>",
"      , 1991, 264(1):84-90.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5350/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9876 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5350=[""].join("\n");
var outline_f5_14_5350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11586341\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219963\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219982\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219966\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219967\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219941\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219927\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9614166\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219943\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219990\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219980\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219946\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219931\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300025\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219936\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219958\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219938\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079710\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219970\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219950\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219951\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219949\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219952\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219930\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219945\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/33/43540?source=related_link\">",
"      Salsalate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5351="Prochlorperazine: Pediatric drug information";
var content_f5_14_5351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prochlorperazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"    see \"Prochlorperazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=see_link\">",
"    see \"Prochlorperazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Compro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prochlorperazine&reg;;",
"     </li>",
"     <li>",
"      Nu-Prochlor;",
"     </li>",
"     <li>",
"      PMS-Prochlorperazine;",
"     </li>",
"     <li>",
"      Sandoz-Prochlorperazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"      see \"Prochlorperazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest possible dose in pediatric patients to decrease incidence of extrapyramidal reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     Children &ge;2 years and weight &ge;9 kg and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9-13 kg: 2.5 mg every 12-24 hours as needed; maximum daily dose: 7.5 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;13-18 kg: 2.5 mg every 8-12 hours as needed; maximum daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;18-39 kg: 2.5 mg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     5 mg every 12 hours as needed; maximum daily dose: 15 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;39 kg: 5-10 mg every 6-8 hours; usual maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Parenteral (as edisylate): Administer based upon patient response, typically every 8-12 hours; convert to oral therapy as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's labeling: I.M.: 0.13 mg/kg/dose; maximum single dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: I.M., I.V.: 0.1-0.15 mg/kg/dose; maximum single dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Migraine, intractable:",
"     </b>",
"     Limited data available: Children &ge;8 years and Adolescents: I.V. (as edisylate): 0.1-0.15 mg/kg as a single dose has been studied in 20 children between the ages of 8-17 years combined with I.V. hydration (Kabbouche, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Psychoses; schizophrenia:",
"     </b>",
"     Children 2-12 years and &ge;9 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5 mg every 8-12 hours; initial maximum daily dose: 10 mg/day on first day; may increase dosage as needed; maximum daily dose: Children 2-5 years: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; Children 6-12 years:  25 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (as edisylate): 0.13 mg/kg/dose, control usually obtained with single dose; change to oral as soon as possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral (tablet): 5-10 mg 3-4 times/",
"     <b>",
"      day",
"     </b>",
"     ; usual maximum: 40 mg/day; larger doses may rarely be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (as edisylate): 5-10 mg every 3-4 hours; usual maximum: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. (as edisylate): 2.5-10 mg; maximum: 10 mg/dose or 40 mg/",
"     <b>",
"      day",
"     </b>",
"     ; may repeat dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal: 25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Surgical nausea/vomiting: Note:",
"     </b>",
"     Should not exceed 40 mg/",
"     <b>",
"      day",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (as edisylate): 5-10 mg 1-2 hours before induction or to control symptoms during or after surgery; may repeat once if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. (as edisylate): 5-10 mg 15-30 minutes before induction or to control symptoms during or after surgery; may repeat once if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antipsychotic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 5-10 mg 3-4 times/day; titrate dose slowly every 2-3 days; doses up to 150 mg/",
"     <b>",
"      day",
"     </b>",
"     may be required in some patients for treatment of severe disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (as edisylate): Initial: 10-20 mg; if necessary repeat initial dose every 1-4 hours to gain control; more than 3-4 doses are rarely needed. If parenteral administration is still required, give 10-20 mg every 4-6 hours; change to oral as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nonpsychotic anxiety:",
"     </b>",
"     Oral (tablet): Usual dose: 15-20 mg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; do not give doses &gt;20 mg/",
"     <b>",
"      day",
"     </b>",
"     or for longer than 12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as edisylate [strength expressed as base]: 5 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compro&reg;: 25 mg (12s) [contains coconut oil, palm oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate [strength expressed as base]: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M. is preferred; avoid I.V. administration; if necessary, may be administered by direct I.V. injection at a maximum rate of 5 mg/minute; do not administer by SubQ route (tissue damage may occur)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F213865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amsacrine, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposome, fluconazole, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, linezolid, melphalan, methotrexate, methylprednisolone sodium succinate, ondansetron, oxaliplatin, paclitaxel, potassium chloride, propofol, remifentanil, sargramostim, sufentanil, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cefepime, etoposide phosphate, fenoldopam, filgrastim, fludarabine, foscarnet, gemcitabine, pantoprazole, pemetrexed, piperacillin/tazobactam, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium gluconate, gallium nitrate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, nalbuphine, pentazocine, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, ketorolac, midazolam, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, morphine sulfate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All dosage forms: Store at controlled room temperature; protect from light. With injection, a clear or slightly yellow solution may be used; incompatible with aminophylline, amphotericin B, ampicillin, calcium salts, cephalothin, foscarnet (Y-site), furosemide, hydrocortisone, hydromorphone, methohexital, midazolam, penicillin G, pentobarbital, phenobarbital, thiopental",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Management of nonsurgical nausea and vomiting [FDA approved in ages &ge;2 years (and at least 9 kg) and adults]; management of surgery-related nausea and vomiting (FDA approved in adults); treatment of acute and chronic psychosis [FDA approved in ages &ge;2 years (and at least 9 kg) and adults]; has also been used for treatment of intractable migraine headaches",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Management of severe nonsurgical nausea and vomiting [FDA approved in ages &ge;2 years (and at least 9 kg) and adults]; treatment of schizophrenia [FDA approved in ages &ge;2 years (and at least 9 kg) and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal: Management of severe nausea and vomiting (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prochlorperazine may be confused with chlorproMAZINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Compazine may be confused with Copaxone&reg;, Coumadin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CPZ (occasional abbreviation for Compazine) is an error-prone abbreviation (mistaken as chlorpromazine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reported with prochlorperazine or other phenothiazines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, cerebral edema, hypotension, peripheral edema, Q-wave distortions, sudden death, T-wave distortions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, altered cerebrospinal fluid proteins, catatonia, coma, cough reflex suppressed, dizziness, drowsiness, fever (mild [I.M.]), headache, hyperpyrexia, impairment of temperature regulation, insomnia, neuroleptic malignant syndrome (NMS), oculogyric crisis, opisthotonos, restlessness, seizure, somnolence, tremulousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, contact dermatitis, epithelial keratopathy, erythema, eczema, exfoliative dermatitis, itching, photosensitivity, skin pigmentation, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia, glucosuria, hyper-/hypoglycemia, lactation, libido (changes in), menstrual irregularity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, atonic colon, constipation, ileus, nausea, obstipation, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculating dysfunction, ejaculatory disturbances, impotence, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Biliary stasis, cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dystonias (torticollis, carpopedal spasm, trismus, protrusion of tongue); extrapyramidal symptoms (pseudoparkinsonism, akathisia, dystonias, tardive dyskinesia, hyperreflexia); SLE-like syndrome, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, lenticular/corneal deposits, miosis, mydriasis, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, laryngeal edema, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, asphyxia, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prochlorperazine or any component; cross-sensitivity with other phenothiazines may exist; avoid use in patients with narrow-angle glaucoma; severe liver or cardiac disease, severe toxic CNS depression or coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;display:inline\">",
"     Additional contraindications for pediatric patients: Infants and children &lt;2 years or &lt;9 kg (20 pounds); management of postoperative nausea and vomiting (pediatric surgery); pediatric conditions for which dosing not described",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9945282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in hepatic and renal impairment. Use with caution in patients at risk for hypotension or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia; hypotension may occur following administration, particularly when parenteral form is used or in high dosages; may also cause orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems; may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention). Use with caution in patients with narrow-angle glaucoma or myasthenia gravis; condition may be exacerbated by cholinergic blockade. Use with caution in patients with Parkinson's disease; patients may be more sensitive to adverse effects. Use with caution in patients at risk of pneumonia (ie, Alzheimer's disease); antipsychotic use has been associated with esophageal dysmotility and aspiration. Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High incidence of extrapyramidal reactions especially in children, reserve use in children &lt;5 years of age to those who are unresponsive to other antiemetics; incidence of extrapyramidal reactions is increased with acute illnesses such as chicken pox, measles, CNS infections, gastroenteritis, and dehydration; extrapyramidal reactions may also be confused with CNS signs of Reye's syndrome or other encephalopathies; avoid use in these clinical conditions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lowers seizure threshold, use cautiously in patients with seizure history; discontinue use at least 48 hours before myelography and do not resume therapy until 24 hours post myelography. Use of antipsychotics in combination with lithium has been associated with an encephalopathy syndrome similar to NMS; monitor patients closely and discontinue treatment if encephalopathic symptomatology develops. Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects. May cause sedation; effects may be potentiated when used with other sedative drugs or ethanol; may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; prochlorperazine is not approved for this indication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of injection in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferoxamine: May enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Prochlorperazine may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1061397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of riboflavin",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and periodic ophthalmic exams (if chronically used)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks postsynaptic mesolimbic dopaminergic receptors in the brain, including the medullary chemoreceptor trigger zone; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 30-40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: Within 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal, oral immediate release: 3-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=see_link\">",
"      see \"Prochlorperazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit caffeine; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Previously recommended rectal dosages in pediatric patients were similar to the oral formulation dosages; however, an appropriate dosage form for rectal administration to pediatric patients is no longer available in the U.S.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kabbouche MA, Vockell AL, LeCates SL, et al, &ldquo;Tolerability and Effectiveness of Prochlorperazine for Intractable Migraine in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(4):E62, www.pediatrics.org/cgi/content/full/107/4/e62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/14/5351/abstract-text/11335783/pubmed\" id=\"11335783\" target=\"_blank\">",
"        11335783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12734 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5351=[""].join("\n");
var outline_f5_14_5351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290570\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213829\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213830\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061387\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061378\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213803\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213787\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061391\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213865\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061382\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061390\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213867\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213864\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061394\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9945282\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061376\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299946\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213796\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061397\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213813\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061386\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061375\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061393\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061384\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061395\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=related_link\">",
"      Prochlorperazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=related_link\">",
"      Prochlorperazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5352="Aluminum toxicity in end-stage renal disease";
var content_f5_14_5352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aluminum toxicity in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5352/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5352/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/14/5352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the glomerular filtration rate falls in chronic renal failure, phosphate retention initiates a sequence of events leading to hyperparathyroidism, vitamin D deficiency, and bone disease. As a result, lowering the serum phosphate concentration with oral phosphate binders has a central role in the management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although aluminum containing antacids were initially used to lower serum phosphate concentrations, the recognition of chronic aluminum toxicity due to absorption and retention of some of the administered aluminum led to the preferential use of alternate phosphate binders such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    , and lanthanum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There appears to be no safe dose of aluminum in chronic renal failure that is also large enough to control the serum phosphate concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of aluminum toxicity in end-stage renal disease is presented in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The declining use of aluminum containing antacids, improved water purification systems, and use of high flux dialyzers has resulted in an extremely low incidence of abnormal aluminum levels among current dialysis patients. One retrospective study examined serum aluminum levels in over 200 patients for the period January 2000 to April 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of elevated aluminum levels among adult dialysis patients was only 2 to 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOURCES OF ALUMINUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodialysis patient can be exposed to aluminum in medications and in the dialysate water. The initial descriptions of outbreaks of dementia in dialysis patients occurred in areas in which there was significant aluminum contamination of the local water supply. This is no longer a problem with the improved methods of water purification now in use, although occasional clusters of cases are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=see_link\">",
"     \"Contaminants in water used for hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute neurotoxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Currently, aluminum-containing antacids are the major source of aluminum ingestion in patients with advanced renal failure. Although the substitution of calcium- and non-calcium based phosphate binders has led to a reduction in the incidence of aluminum toxicity, some patients with refractory hyperphosphatemia or calcium-induced hypercalcemia still require short-term aluminum therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. Other oral and injectable medications administered to dialysis patients may also contain aluminum as an impurity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/8\">",
"     8",
"    </a>",
"    ]. Routine serum aluminum testing in dialysis units is still appropriate as aluminum contamination of dialysate through unanticipated sources is occasionally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow accumulation of aluminum over a period of years can lead to a number of clinical manifestations, including osteomalacia, bone and muscle pain, an iron-resistant microcytic anemia, hypercalcemia, and neurologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Acute aluminum neurologic toxicity, which can be fatal, is also observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Osteomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is the type of renal osteodystrophy most frequently caused by aluminum excess; however, due to reduced use of aluminum, its prevalence has markedly decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. Osteomalacia is characterized by reductions in bone turnover and the number of bone-forming and bone-resorbing cells, and an increase in the volume of unmineralized bone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It had been assumed that vitamin D deficiency played an important role in the genesis of this lesion, but most cases appear to result from aluminum intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adynamic bone disease, a form of renal osteodystrophy, is a common finding in both peritoneal dialysis and hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. Although aluminum accumulation may contribute in a minority of cases, excessive suppression of PTH release plays a more important role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PTH appears to protect against aluminum deposition at the mineralization front, perhaps by increasing bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/2\">",
"     2",
"    </a>",
"    ]. This relationship becomes important clinically because aluminum bone disease must be excluded in patients being considered for parathyroidectomy, since lowering PTH levels can lead to accelerated bone aluminum deposition in patients with concurrent osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .) Lowering PTH levels medically by the administration of calcitriol also may accelerate aluminum bone disease.",
"   </p>",
"   <p>",
"    Patients with aluminum excess complain of generalized bone and joint pain and muscle weakness. The joint symptoms may reflect aluminum concentrations in the synovial fluid that can be two to 10 times higher in patients taking aluminum-containing antacids than in those treated with other phosphate binders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although aluminum bone disease can occur in any patient treated with aluminum, the risk is greater in diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This may be related to a lower than normal bone formation rate, an abnormality that can be demonstrated in type 1 diabetics prior to the onset of clinical renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Why this occurs is not well understood but these patients tend to have lower serum levels of PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aluminum accumulation can impair red cell production. This effect is manifested clinically by a reversible microcytic anemia that is present without evidence of iron deficiency and is resistant to iron supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5,15\">",
"     5,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia may result from aluminum-related bone disease. It should be suspected in the patient who does not have marked elevations in serum intact PTH (eg, less than 500",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    or who is not taking vitamin D therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis encephalopathy is a neurologic syndrome developing in long-term dialysis patients that is characterized by myoclonus, mental changes, speech disturbances, hallucinations, and seizures. Increased aluminum is present in the brain tissue of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/16\">",
"     16",
"    </a>",
"    ]. The original reports noted geographic clustering of cases in areas with aluminum contaminated water. With the introduction of adequate water purification measures, reported cases have virtually disappeared [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible, however, that long-term and more subtle central nervous system toxicity is a problem. As previously noted, no dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    has been shown to be both safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/4\">",
"     4",
"    </a>",
"    ]. A postmortem study of dialysis patients who had been treated with aluminum demonstrated changes in tau protein processing in the brain that are similar to those seen in Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinical significance of these findings is uncertain. None of the 15 patients had signs of dialysis encephalopathy; one had some signs of cognitive impairment, although it is not clear if this was related to aluminum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential problem is acute aluminum neurologic toxicity, which is characterized by mental status changes, coma, seizures, and a high incidence of death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. This is most frequently caused by exposure to high levels of aluminum contamination in the dialysate. In this setting, most patients in the same dialysis center become ill simultaneously, and measured plasma aluminum levels are frequently elevated to approximately 400 to 1000",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"   </p>",
"   <p>",
"    Acute",
"    aluminum toxicity can also occur in non-dialysis patients with severe renal dysfunction (glomerular filtration rates less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) who are given aluminum gels plus sodium citrate. Citrate markedly enhances intestinal aluminum absorption (",
"    <a class=\"graphic graphic_figure graphicRef55777 \" href=\"UTD.htm?12/8/12429\">",
"     figure 1",
"    </a>",
"    ) both by keeping aluminum soluble (via the formation of aluminum citrate) and by complexing with calcium in the intestinal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome has also been observed in patients with large body stores of aluminum who are given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO) at doses of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    This complication and methods that have been introduced to help avoid this adverse effect are discussed in multiple sections in this topic review. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Acute complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCREENING AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is sometimes difficult to determine which patients have aluminum-related disease and will benefit from aluminum removal, since",
"    <strong>",
"     unstimulated",
"    </strong>",
"    serum aluminum concentrations are randomly distributed and do not correlate with time on dialysis or with the presence of bone aluminum deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In general, however, excess aluminum deposition is unlikely in patients with baseline unstimulated serum aluminum concentrations less than 20",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Post-DFO increase in serum aluminum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rise in serum aluminum concentration after an intravenous infusion of DFO has marked diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/23\">",
"     23",
"    </a>",
"    ]. In one study of 50 consecutive dialysis patients undergoing bone biopsy, 20 had no identifiable bone aluminum accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/21\">",
"     21",
"    </a>",
"    ]. These patients were distinguishable from those with a positive bone aluminum stain by a smaller increase in serum aluminum after DFO stimulation and a higher baseline serum PTH concentration.",
"   </p>",
"   <p>",
"    The diagnostic sensitivity of stimulated changes in serum aluminum and PTH was also evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most sensitive test for aluminum bone disease was a stimulated increase in serum aluminum concentration to 200",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      <span class=\"nowrap\">",
"       (ng/mL)",
"      </span>",
"      or more.",
"     </li>",
"     <li>",
"      The most specific test was a pre-DFO serum aluminum concentration of greater than 200",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      or the combination of stimulated increase in serum aluminum of more than 200",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      plus a low serum PTH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, case reports have suggested that the doses used for the DFO test in the previous study (40",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be associated with ophthalmologic damage and mucormycosis (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Ocular and auditory neurotoxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37849?source=see_link\">",
"     \"Non-access related infections in chronic dialysis patients\"",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the reluctance to use the 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    test dose, lower doses have been evaluated for diagnostic efficacy. In a study using 5 and 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    test doses in 77 hemodialysis patients who also underwent bone biopsies, the combination of a low intact PTH level (less than 150",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    and a rise in the serum aluminum of more than 50",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    after the test dose had a 87 and 95 percent sensitivity and specificity, respectively, for the detection of aluminum bone disease as determined by bone biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/25\">",
"     25",
"    </a>",
"    ]. Both the 5 and 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight test doses were similarly accurate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recommendations and K/DOQI guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is obtaining a baseline serum aluminum concentration. We and the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group recommend that a subsequent low dose DFO test be administered in the dialysis patient suspected of having aluminum overload or toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. This includes patients with elevated serum aluminum levels (between 60 to 200",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs suggestive of aluminum toxicity (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above). The test should also be done prior to parathyroid surgery in those with a history of exposure to aluminum. To help avoid toxicity, the low dose DFO test should",
"    <strong>",
"     not",
"    </strong>",
"    be performed in patients with serum aluminum levels above 200",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"   </p>",
"   <p>",
"    With",
"    the low dose test, DFO at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered one hour prior to the end of the dialysis session. Serum aluminum is measured prior to and two days after the DFO infusion (before the next dialysis session). The test is considered positive if there is an increase in serum aluminum of &ge;50",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"   </p>",
"   <p>",
"    The presence of aluminum bone disease is consistent with a positive DFO test plus low serum levels of intact PTH (less than 150",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the definitive diagnostic test for aluminum bone disease is a bone biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of aluminum-induced toxicity other than bone disease is based upon the presence of the characteristic clinical features previously described, combined with the baseline serum aluminum and results from the low dose DFO test. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of excess aluminum using the chelator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO) can reverse osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], aluminum-induced anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/15\">",
"     15",
"    </a>",
"    ], and acute encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. Long-term DFO therapy reduces bone aluminum staining and improves bone histology such that patients with osteomalacia tend to change to a mixed lesion or to osteitis fibrosa that is characteristic of secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .) In comparison, patients who have undergone parathyroidectomy and have low bone turnover may show little improvement in the bone disease following DFO. Removal of excess aluminum using DFO can also reverse aluminum-induced anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/15\">",
"     15",
"    </a>",
"    ] and encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of DFO therapy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ], but prolonged periods may be required. As an example, one study evaluated 18 patients with aluminum-related bone disease who received one year of DFO while they continued to receive aluminum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/27\">",
"     27",
"    </a>",
"    ]. A decrease in stainable trabecular bone aluminum and elevations in osteoblastic osteoid, osteoclast number, and bone formation rate were observed. These indices also improved in previously parathyroidectomized patients. In contrast to the clear histologic benefit, only moderate relief of symptoms was noted.",
"   </p>",
"   <p>",
"    However, the published studies showing benefits with prolonged chelation therapy on bone biopsy were performed prior to the use of newer and more efficient techniques to remove DFO-aluminum complexes. Compared with cuprophane membranes, for example, high-flux polysulfone dialyzer membranes have a four-fold greater clearance of the DFO-aluminum complex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, DFO was also used at relatively high doses (20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body) in the earlier studies, which are associated with an increased risk of adverse effects (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Adverse effects of DFO'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of studies that have reported neurologic and other organ improvement in patients treated with more efficient dialysis techniques as well as low dose DFO regimens. One six month trial, for example, evaluated the possible neurologic benefits of low dose DFO among 42 patients acutely exposed to dialysate aluminum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/29\">",
"     29",
"    </a>",
"    ]. Initially, patients were treated with intensive",
"    <span class=\"nowrap\">",
"     hemodialysis/hemoperfusion",
"    </span>",
"    to lower serum aluminum levels. Low dose DFO (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered weekly) was subsequently given only after such",
"    <span class=\"nowrap\">",
"     hemodialysis/hemoperfusion",
"    </span>",
"    therapy had adequately lowered basal as well as post-DFO infusion serum aluminum concentrations. The chelator was also administered five hours prior to the dialysis session to facilitate removal of the DFO-aluminum complex.",
"   </p>",
"   <p>",
"    At six months, this strategy resulted in markedly lower baseline serum aluminum and incremental serum aluminum levels after DFO infusion. In addition, increases in mean corpuscular volume and serum intact PTH were noted, while neurologic and ophthalmologic symptoms were not observed.",
"   </p>",
"   <p>",
"    An important related issue is the optimal method of removing the DFO-aluminum complex to maximize its elimination, while minimizing organ exposure to any possible toxic effects. Some important variables include the exact timing of the dialysis session with respect to DFO administration, the type of dialysis membrane or cartridge, and the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    length of time of",
"    <span class=\"nowrap\">",
"     DFO/dialysis",
"    </span>",
"    administration.",
"   </p>",
"   <p>",
"    Overall, compared with cuprophan membranes, dialysis using high flux membranes or hemoperfusion with a charcoal filter are superior in removing the DFO-aluminum complex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, administering DFO four to six hours prior to the next dialysis session with a high-flux hemodialysis membrane and giving DFO at most every week appears to maximize complex removal, while lowering the risk of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent of efficacy with respect to specific organ involvement, a strategy based upon intensive",
"    <span class=\"nowrap\">",
"     hemodialysis/hemoperfusion",
"    </span>",
"    therapy using high flux dialysis membranes and the administration of weekly low dose DFO may",
"    <strong>",
"     minimize",
"    </strong>",
"    the risk of adverse effects with DFO therapy, particularly mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ]. The evidence supporting this observation is only indirect, as it is based upon the absence of reported and perceived cases of mucormycosis among patients treated with this approach. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adverse effects of DFO'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and discontinuation of the source of aluminum is the first step in all patients with baseline serum aluminum levels greater than 60",
"    <span class=\"nowrap\">",
"     &micro;g/L,",
"    </span>",
"    a positive low dose DFO test,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical symptoms suggestive of aluminum toxicity. The optimal approach to the",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    patient with aluminum overload, including the role of DFO, is uncertain. We do",
"    <strong>",
"     not",
"    </strong>",
"    administer DFO to asymptomatic patients with aluminum overload, as the risk of DFO toxicity outweighs any known benefit to such patients. Such patients should be carefully monitored. The issues that should be taken into account are discussed elsewhere. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We agree with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group recommendation of the following protocol for the management of",
"    <strong>",
"     symptomatic",
"    </strong>",
"    patients with aluminum toxicity; this approach relies upon the absolute serum aluminum concentration and the rise in serum aluminum after a low dose DFO test. The strategy attempts to maximize aluminum removal and organ benefits, while minimizing the risk of adverse effects with DFO therapy.",
"   </p>",
"   <p>",
"    The first step is to obtain a baseline serum aluminum concentration. Patients with values above 200",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    are at risk for neurotoxicity with DFO. As a result, DFO should",
"    <strong>",
"     not",
"    </strong>",
"    be administered to such patients, including for the low dose test, until the serum aluminum concentration is lowered to safer levels by intensive dialysis (six times per week) with a high-flux membrane and a dialysate aluminum concentration of less than 5",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"    In addition, all aluminum intake must be stopped. These measures are continued for at least four to six weeks and until serum aluminum levels are less than 200",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"   </p>",
"   <p>",
"    If the baseline serum aluminum is",
"    <strong>",
"     less",
"    </strong>",
"    than 200",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    or becomes less than 200",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    after intensive hemodialysis, a low dose DFO test is performed (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Recommendations and K/DOQI guidelines'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In this setting, different treatment regimens are recommended based upon the rise in serum aluminum with a low dose DFO test and the presence or absence of side effects with the test:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rise greater than 300",
"       <span class=\"nowrap\">",
"        &micro;g/L",
"       </span>",
"       or there are side effects",
"      </strong>",
"      &mdash; If the serum aluminum rises &ge;300",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      or there are side effects, DFO at 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is administered once per week for",
"      <strong>",
"       four months",
"      </strong>",
"      . The DFO is given intravenously over a one hour period and five hours prior to the performance of high efficiency hemodialysis. This strategy should maximize removal of the DFO-aluminum complex, while minimizing patient exposure to its toxic effects. After four months of such therapy, DFO is withheld for one month.",
"      <br/>",
"      <br/>",
"      A DFO test is subsequently performed. If the serum aluminum again rises &ge;300",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      or there are side effects, management is the same as noted in the previous paragraph. If the serum aluminum rises to between 50 to 299",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, the patient is managed as described in the next paragraph. If the rise is less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, DFO is withheld for four months. DFO is stopped if, on repeat DFO testing, the rise in serum aluminum is less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L.",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Rise between 50 to 299",
"       <span class=\"nowrap\">",
"        &micro;g/L",
"       </span>",
"       and no side effects",
"      </strong>",
"      &mdash; If the serum aluminum rises between 50 to 299",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, DFO at 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is administered once per week for",
"      <strong>",
"       two months",
"      </strong>",
"      . In this setting, DFO is given intravenously over the last hour of hemodialysis. High efficiency hemodialysis is performed 44 hours later. After two months of such therapy, DFO is withheld for one month.",
"      <br/>",
"      <br/>",
"      A DFO test is subsequently performed. If the rise in serum aluminum is again between 50 to 299",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, management is the same as noted in the previous paragraph. If the rise is less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, DFO is withheld for four months. DFO is stopped if, on repeat testing after this period, the rise is less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L.",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Rise less than 50",
"       <span class=\"nowrap\">",
"        &micro;g/L",
"       </span>",
"       and no side effects",
"      </strong>",
"      &mdash; If the serum aluminum rises less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L",
"      </span>",
"      and there are no side effects, DFO is not given for one month. A repeat DFO test is then performed. If the rise is again less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L,",
"      </span>",
"      then DFO is withheld for four months. DFO is stopped if, on repeat testing, the rise in serum aluminum is again less than 50",
"      <span class=\"nowrap\">",
"       &micro;g/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF DFO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious side effects with DFO therapy include mucormycosis and neurotoxicity. An increased risk of these adverse effects are observed among patients with high serum aluminum levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment with high doses of DFO.",
"   </p>",
"   <p>",
"    Methods have therefore been introduced in an attempt to decrease the risk of such adverse effects. Various aspects of therapy previously recommended, such as daily high efficiency hemodialysis until DFO therapy is safe to administer, low dose weekly DFO therapy, use of high flux hemodialysis membranes, and appropriate timing of DFO administration with respect to a hemodialysis session, should help limit the risk of serious side effects with DFO therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the following discussion, the incidence and types of adverse effects were largely described during a period in which such preventive measures were not performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international registry of mucormycosis in dialysis patients seen up to 1991 had a total of 59 patients; 78 percent were receiving DFO [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/24\">",
"     24",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients had received a large weekly dose of DFO (3.3",
"      <span class=\"nowrap\">",
"       g/week),",
"      </span>",
"      but 20 percent had received 1.5",
"      <span class=\"nowrap\">",
"       g/week",
"      </span>",
"      or less.",
"     </li>",
"     <li>",
"      Only 30 percent had a known risk factor for this opportunistic fungal infection (such diabetes mellitus, leukemia, or immunosuppressive drugs).",
"     </li>",
"     <li>",
"      44 percent had disseminated disease at presentation, while 31 percent had rhinocerebral involvement.",
"     </li>",
"     <li>",
"      Almost 90 percent of cases were fatal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    increases the risk of mucormycosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H4#H4\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Deferoxamine and iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ocular and auditory neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular and auditory neurotoxicity are other serious side effects that have been reported with chronic higher dose therapy. In a series of 89 patients receiving nightly subcutaneous DFO for transfusional iron overload, 13 presented with the acute onset of visual loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deafness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/30\">",
"     30",
"    </a>",
"    ]. Detailed ophthalmologic, audiologic, and evoked-potential studies uncovered abnormalities caused by neurotoxicity in another 27 patients. Thus, patients treated with DFO should be referred to ophthalmology and otorhinolaryngology for baseline and yearly examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;DFO can also cause acute complications such as gastrointestinal disturbances, hypotension, anaphylaxis, and",
"    <strong>",
"     worsening",
"    </strong>",
"    of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The last effect may result from transiently increased concentrations of aluminum in the cerebrospinal fluid due to passage of the DFO-aluminum complex (mol wt 600) across the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5352/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute neurotoxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195553226\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aluminum toxicity is now a rare occurrence in the hemodialysis population due to better understanding of its cause, reliance on non-aluminum containing antacids, improved water purification systems, and use of high flux dialyzers. The hemodialysis patient can be exposed to aluminum in medications and in the dialysate water. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Sources of aluminum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Slow accumulation of aluminum over a period of years can lead to a number of clinical manifestations, including osteomalacia, bone and muscle pain, an iron-resistant microcytic anemia, hypercalcemia, and neurologic abnormalities. Acute aluminum neurologic toxicity, which can be fatal, is also observed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The condition is unlikely to be present in patients with an unstimulated serum aluminum concentration less than 20",
"      <span class=\"nowrap\">",
"       ug/L.",
"      </span>",
"      When the condition is suspected, the degree of rise in serum aluminum following an intravenous infusion of DFO (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      ) is a useful guide to determine which patients require further study and treatment. However, the DFO test has been associated with significant toxicity. The approach to screening, diagnosis, and treatment of aluminum toxicity depends upon the presence or absence of symptoms, serum aluminum levels, toxicity associated with the DFO screening test, and toxicity associated with therapy. The",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      work group algorithms should be used to guide the diagnosis and treatment of aluminum toxicity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Serious side effects with DFO therapy include mucormycosis and neurotoxicity. An increased risk of these adverse effects is observed among patients with high serum aluminum levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment with high doses of DFO. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adverse effects of DFO'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/1\">",
"      Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/2\">",
"      Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/3\">",
"      Cannata-And&iacute;a JB, Fern&aacute;ndez-Mart&iacute;n JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17 Suppl 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/4\">",
"      Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/5\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/6\">",
"      Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis 2005; 46:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Elevated serum aluminum levels in hemodialysis patients associated with use of electric pumps--Wyoming, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/8\">",
"      Bohrer D, Bertagnolli DC, de Oliveira SM, et al. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant 2007; 22:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/9\">",
"      Netter P, Kessler M, Burnel D, et al. Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds. J Rheumatol 1984; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/10\">",
"      Andress DL, Kopp JB, Maloney NA, et al. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 1987; 316:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/11\">",
"      Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/12\">",
"      Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/13\">",
"      Santiago JV, McAlister WH, Ratzan SK, et al. Decreased cortical thickness &amp; osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 1977; 45:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/14\">",
"      Vincenti F, Hattner R, Amend WJ Jr, et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/15\">",
"      Touam M, Martinez F, Lacour B, et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol 1983; 19:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/16\">",
"      Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/17\">",
"      Harrington CR, Wischik CM, McArthur FK, et al. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 1994; 343:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/18\">",
"      Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/19\">",
"      Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med 1990; 150:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/20\">",
"      Chazan JA, Abuelo JG, Blonsky SL. Plasma aluminum levels (unstimulated and stimulated): clinical and biochemical findings in 185 patients undergoing chronic hemodialysis for 4 to 95 months. Am J Kidney Dis 1989; 13:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/21\">",
"      McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 1990; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/22\">",
"      Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999; 34:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/23\">",
"      Milliner DS, Nebeker HG, Ott SM, et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984; 101:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/24\">",
"      Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/25\">",
"      D'Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/26\">",
"      Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984; 311:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/27\">",
"      Felsenfeld AJ, Rodriguez M, Coleman M, et al. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989; 35:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/28\">",
"      Molitoris BA, Alfrey AC, Alfrey PS, Miller NL. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 1988; 34:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/29\">",
"      Barata JD, D'Haese PC, Pires C, et al. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/30\">",
"      Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/31\">",
"      Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 1988; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/32\">",
"      Knudsen PJ, Leon J, Ng AK, et al. Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 synthesis and release by mononuclear phagocytes. Nephron 1989; 53:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5352/abstract/33\">",
"      Ellenberg R, King AL, Sica DA, et al. Cerebrospinal fluid aluminum levels following deferoxamine. Am J Kidney Dis 1990; 16:157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1839 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5352=[""].join("\n");
var outline_f5_14_5352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H195553226\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOURCES OF ALUMINUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCREENING AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Post-DFO increase in serum aluminum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recommendations and K/DOQI guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADVERSE EFFECTS OF DFO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ocular and auditory neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195553226\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1839|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/8/12429\" title=\"figure 1\">",
"      Citrate and aluminum absorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37849?source=related_link\">",
"      Non-access related infections in chronic dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5353="Anterior neck anatomy";
var content_f5_14_5353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Anterior neck anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterosuperior view of a dissection of the root of the neck. The brachial plexus and the third part of the subclavian artery emerge&nbsp;between the anterior and middle scalene muscles.",
"    <div class=\"footnotes\">",
"     L. recurrent laryngeal: left recurrent laryngeal.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5353=[""].join("\n");
var outline_f5_14_5353=null;
var title_f5_14_5354="Corticobasal degeneration";
var content_f5_14_5354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Corticobasal degeneration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Stewart A Factor, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Deborah G Walls, APRN-BC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/14/5354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/14/5354/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/14/5354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H100657524\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticobasal degeneration (CBD) is a rare neurodegenerative disorder that poses significant challenges to clinical diagnosis and treatment. The classic description of CBD is that of a progressive asymmetric movement disorder characterized by various combinations of akinesia, rigidity, dystonia, focal myoclonus, ideomotor apraxia, and alien-limb phenomena. However, a wider range of clinical presentations is increasingly apparent, including onset with cognitive or behavioral abnormalities.",
"   </p>",
"   <p>",
"    This topic will review clinical aspects of CBD. Other atypical parkinsonian disorders are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=see_link\">",
"     \"Progressive supranuclear palsy (PSP)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=see_link\">",
"     \"Multiple system atrophy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743066\">",
"    <span class=\"h1\">",
"     HISTORICAL ASPECTS AND NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first description of corticobasal degeneration (CBD) in 1967 reported the disorder in three patients who had an asymmetric, akinetic-rigid neurodegenerative syndrome with cerebral cortical dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The original name given to this was \"corticodentatonigral degeneration with neuronal achromasia,\" based upon its neuropathologic appearance. It would be another two decades before the next series of six patients was described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/3\">",
"     3",
"    </a>",
"    ]. However, as subsequent cases were evaluated, it became apparent that the dentate pathology was infrequent and the nomenclature evolved to the more accurate terminology of corticobasal or corticobasal ganglionic degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is now recognized that pathologically proven CBD often begins as a cognitive or behavioral disturbance. Additionally, the cognitive and motor features considered characteristic of CBD are not specific to CBD, but may occur with other pathologically proven neurodegenerative disorders, including progressive supranuclear palsy, frontotemporal dementia, and Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. This has led some experts to the use the term &ldquo;corticobasal syndrome&rdquo; (CBS) for cases with a clinical diagnosis, while reserving &ldquo;corticobasal degeneration&rdquo; for cases with neuropathologic confirmation.",
"   </p>",
"   <p>",
"    A fundamental abnormality of the cytoskeletal protein tau is the underlying pathologic substrate, which has led to CBD being labeled as a tauopathy. Other tauopathies include Alzheimer disease, Pick disease (frontotemporal dementia) and progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The shared tau protein pathology may explain the overlap of clinical symptoms and the complex neuropathology present in these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743073\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated annual incidence of CBD ranges from 0.62 to 0.92 per 100,000 population, with an estimated prevalence of approximately 5 to 7 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the precise incidence and prevalence of CBD are unknown. Several factors, including the lack of validated and widely accepted diagnostic criteria, and the increasingly recognized clinical and neuropathologic heterogeneity of the disease, have prevented large epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease typically presents in the sixth to eighth decades of life with onset of symptoms occurring at a mean age of 61 to 63 years in different reports [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The youngest case with pathologic confirmation had the onset of symptoms at age 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"     12",
"    </a>",
"    ], while the youngest case of clinically probable CBD had onset of symptoms at age 28 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/14\">",
"     14",
"    </a>",
"    ]. Some authors report an unequal gender distribution suggesting a predominance in women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ], but other reports have found no gender preference [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease is considered to occur sporadically, although rare familial cases of CBD have been reported, leading to the possibility that there may be a genetic basis for at least a predisposition to the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/9\">",
"     9",
"    </a>",
"    ]. No environmental contribution such as exposure to toxic or infectious agents has been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743080\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic description of CBD is that of a progressive asymmetric movement disorder with symptoms initially affecting one limb, including various combinations of akinesia and extreme rigidity, dystonia, focal myoclonus, ideomotor apraxia, and alien limb phenomena (",
"    <a class=\"graphic graphic_table graphicRef55825 \" href=\"UTD.htm?34/5/34908\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/2,12,15,18\">",
"     2,12,15,18",
"    </a>",
"    ]. However, most of the early reports describing the clinical features of CBD were retrospective case series from movement disorder centers that may have led to a referral bias in emphasizing the motor symptoms. It is now recognized that the clinical features are heterogeneous, including varied motor pictures. In some cases the symptoms can be symmetric instead of the classic asymmetric presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, it has been found that cognitive impairment is a common manifestation of CBD and may be a presenting feature, while the parkinsonian motor features may emerge later as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/13,20-22\">",
"     13,20-22",
"    </a>",
"    ]. Important cognitive features of CBD include executive dysfunction, aphasia, apraxia, behavioral change, and visuospatial dysfunction, with relatively preserved episodic memory. The heterogeneity is likely a reflection of the topographical variations in pathological lesions in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the range of findings reported for CBD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 18 patients with an autopsy diagnosis of CBD, the dominant clinical syndromes at presentation were a combination of dysexecutive and motor features in 7, progressive nonfluent aphasia in 5, and the behavioral variant of frontotemporal dementia in 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 14 autopsy-proven cases of CBD, the most common features at disease onset were an asymmetric clumsiness of a limb, with or without rigidity in 7 patients, a gait disorder in 5, sensory problems in 4, tremor, cognitive problems, behavioral changes in 3 patients each, and speech disorder in 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"       12",
"      </a>",
"      ]. The mean time to first visit to a neurologist was three years, and the most prevalent symptoms at that time were an asymmetric limb bradykinesia or rigidity (8 patients) and ideomotor apraxia (7 patients). Despite these features, only 5 of the 14 patients were diagnosed during life with CBD, highlighting the difficulty in making the correct antemortem diagnosis.",
"     </li>",
"     <li>",
"      In a later series of 15 pathologically proven cases of CBD, the presenting complaints were exclusively cognitive for 8 patients, both cognitive and motor for 4 patients, and exclusively motor for 3 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/13\">",
"       13",
"      </a>",
"      ]. The cognitive problems primarily involved impairments of speech, language, visuospatial, social, and executive function. The most frequent motor complaints at presentation were related to gait difficulty, while the most frequent motor signs were unilateral limb rigidity or axial rigidity. With disease progression, extrapyramidal problems emerged or worsened in the majority of patients, and executive dysfunction developed in all patients prior to death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172630660\">",
"    <span class=\"h2\">",
"     Motor and gait involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common motor symptoms of CBD include rigidity, myoclonus, dystonia, and gait impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/2,12,18,24\">",
"     2,12,18,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, motor symptoms begin in one limb. Rigidity can be profound with and without cogwheeling. Dystonia involves abnormal posturing of the hand (opened or closed) or foot (toe curling and foot inversion) that quickly becomes fixed. Along with apraxia (see",
"    <a class=\"local\" href=\"#H168534479\">",
"     'Cortical dysfunction and apraxia'",
"    </a>",
"    below), the affected limb is rendered useless [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. While axial rigidity, typical of progressive supranuclear palsy, is sometimes seen, the appendicular rigidity is notably more severe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12,27\">",
"     12,27",
"    </a>",
"    ]. Symptoms ultimately progress to involve all four limbs.",
"   </p>",
"   <p>",
"    The gait in CBD is variable but can be bradykinetic, short stepped, and shuffling, similar to the gait of typical Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/28\">",
"     28",
"    </a>",
"    ]. There is typically no arm swing in the affected upper limb which is often flexed and held against the body. A wide based, &ldquo;frontal lobe&rdquo; or freezing gait is typical of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Freezing of gait occurs in &gt;50 percent of patients within six years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/29\">",
"     29",
"    </a>",
"    ]. It may be seen even earlier, as 8 percent will have it in three years, and rarely CBD may present with gait freezing as primary progressive freezing gait [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/30\">",
"     30",
"    </a>",
"    ]. Postural instability is considered a later feature. However one study suggested that gait difficulty and a propensity to fall can be the earliest motor feature [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"     22",
"    </a>",
"    ]. Occasionally, some patients can develop leg apraxia, making it impossible to walk. Tremor is seen less frequently than in idiopathic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/17\">",
"     17",
"    </a>",
"    ] and is more of a rapid (6 to 8 hertz)",
"    <span class=\"nowrap\">",
"     postural/action",
"    </span>",
"    tremor, often described as irregular and jerky [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15\">",
"     15",
"    </a>",
"    ] and sometimes mistaken for the classic resting tremor of Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. Myoclonus is typically present, and it can result from sensory or motor stimulation or action of the affected limb. The myoclonus is probably related to an enhanced, long-loop reflex with a pathway that is probably different from classic cortical reflex myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172641960\">",
"    <span class=\"h2\">",
"     Speech alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech is affected in 90 percent or more of patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12,33\">",
"     12,33",
"    </a>",
"    ]. Dysarthria is prominent and usually an early feature. Characteristics are mixed and varied. About one-third of patients have the hypokinetic form, similar to the type seen in idiopathic Parkinson disease, that is characterized by reduced volume, monotone pitch, fluctuating speech articulation, shallow inhalations, and a slow rate of speech punctuated with rapid-burst [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/33\">",
"     33",
"    </a>",
"    ]. Other less common forms include mixed dysarthrias with varied features of spasticity and pseudobulbar speech, strained strangulated voice with prolongation of sounds similar to spasmodic dysphonia, and hypernasality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172641856\">",
"    <span class=\"h2\">",
"     Oculomotor dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculomotor dysfunction is common in CBD. In one small study, patients with typical CBD had increased horizontal saccadic latencies ipsilateral to the side affected by apraxia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/34\">",
"     34",
"    </a>",
"    ]. Vertical saccades are usually normal or only mildly affected as compared with progressive supranuclear palsy, where vertical saccades are characteristically severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/35\">",
"     35",
"    </a>",
"    ]. Pursuit eye movements are slow and saccadic with the appearance of several steps to reach a target [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/36\">",
"     36",
"    </a>",
"    ]. Difficulty in initiating saccades on command is seen, although spontaneous saccades remain normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/37\">",
"     37",
"    </a>",
"    ]. This represents a form of ocular apraxia. Supranuclear gaze palsy in CBD can mimic the oculomotor findings of progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/7,13\">",
"     7,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168534479\">",
"    <span class=\"h2\">",
"     Cortical dysfunction and apraxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical dysfunction is also common in CBD, hence the name. Apraxia is a frequent manifestation of cortical dysfunction and is defined as difficulty performing learned and purposeful skilled movements despite having the desire and ability to do so; it is not explained by deficits in comprehension or elemental motor or sensory function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various types of apraxia are observed in CBD, including ideomotor apraxia (inability to perform goal-directed movements) and ideational apraxia (inability to coordinate activities that require multiple sequential movements). With ideomotor apraxia, the most frequent type in CBD, unilateral damage to the dominant hemisphere and supplemental motor area can produce bilateral symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Ideational apraxias tend to occur in more advanced stages of CBD and in Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/39\">",
"     39",
"    </a>",
"    ]. Apraxia may occur any time in the course of illness, including before the emergence of dystonia and myoclonus. In such cases, the apraxia alone may render the hand useless. Apraxia may also present after the onset of other motor symptoms and may then be difficult to detect because rigidity, dystonia, and myoclonus can themselves prevent the proper performance of skilled movements. The usual complaint of the patient is that the limb will not do what they want it to do. Apraxia is usually associated with cortical sensory loss such as agraphesthesia and astereognosis. Patients may complain of numbness and tingling, and examination may also demonstrate impaired two-point discrimination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/9,36\">",
"     9,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172631425\">",
"    <span class=\"h3\">",
"     Alien limb phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another manifestation of cortical dysfunction in CBD is the alien limb phenomena, which is seen in up to 50 percent of patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12,41\">",
"     12,41",
"    </a>",
"    ]. It can affect the arm or leg and is described as a feeling that the limb does not belong to the subject or that it has a will of its own. The limb moves outside of voluntary control with complex movements beyond simple levitation. It can appear to the observer that the limb is in constant motion, grabbing the other hand or other object. Although a striking feature when present, it is not pathognomonic for CBD, but should increase consideration for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/17,42,43\">",
"     17,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85747391\">",
"    <span class=\"h3\">",
"     Aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language problems associated with CBD range from mild phonologic impairments to severe progressive nonfluent aphasia, a type of aphasia that sometimes observed in other tauopathies, including frontotemporal dementia and Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/13,20,44-46\">",
"     13,20,44-46",
"    </a>",
"    ]. In patients with CBD, aphasia is usually noted earlier in those with cognitive-onset CBD compared with those who have motor-onset CBD. However, aphasia usually develops with disease progression in patients with motor-onset CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H5#H5\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Progressive nonfluent aphasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168534501\">",
"    <span class=\"h3\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive decline, initially thought to be rare with CBD, is increasingly recognized as another prominent feature that may have been previously under reported, especially as a presenting or early symptom, due to the bias of case reports coming from movement disorder centers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11,47,48\">",
"     11,47,48",
"    </a>",
"    ]. In one case series of 11 neuropathologically-diagnosed patients with CBD, early dementia was noted in 6, and cognitive impairment eventually developed in all [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11\">",
"     11",
"    </a>",
"    ]. In another case series of 13 autopsy proven cases of CBD, dementia was the most common presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/47\">",
"     47",
"    </a>",
"    ]. Only 4 out of the 13 cases had an antemortem diagnosis of CBD, while six others were clinically diagnosed (incorrectly) as having Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/47\">",
"     47",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Neuropsychological testing of patients with suspected CBD shows patterns distinctly different from those of patients diagnosed with Alzheimer disease (AD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/49\">",
"     49",
"    </a>",
"    ]. In one study comparing 21 subjects who had CBD with 21 patients who had AD, those with CBD scored better in areas of verbal memory but showed more depression on the Geriatric Depression Scale, whereas patients with AD did better on tests of praxis and motor skills [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/49\">",
"     49",
"    </a>",
"    ]. Both groups performed poorly on tests of attentional skills, as shown in the performance of speed of processing information and mental control. Another report found that learning disabilities could be overcome with verbal cueing in patients with CBD but not in those with AD, owing to the relatively preserved retention abilities in the former [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing the cognitive features of patients with a clinical diagnosis of CBD and progressive supranuclear palsy (PSP), ideomotor apraxia was significantly more frequent in those with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/51\">",
"     51",
"    </a>",
"    ]. Executive function, though abnormal in both, was more severely impaired in those with PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/51\">",
"     51",
"    </a>",
"    ]. However, another study found that patients with CBD had a dysexecutive syndrome similar to that seen in PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85747116\">",
"    <span class=\"h2\">",
"     Behavioral change",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral and neuropsychiatric manifestations of CBD may include depression, compulsive behavior, agitation, irritability, social withdrawal, and apathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168532478\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early stages of CBD, brain imaging with CT and MRI may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/48\">",
"     48",
"    </a>",
"    ]. As the disease progresses, abnormalities in the form of asymmetric cortical atrophy are observed in up to half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Focal atrophy predominantly involves the posterior frontal and parietal regions, along with dilatation of the lateral ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/57\">",
"     57",
"    </a>",
"    ]. Atrophy of the corpus callosum is also detectable on imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/51,57,58\">",
"     51,57,58",
"    </a>",
"    ]. On T2-weighted images, there is signal hyperintensity of the atrophic cortex and underlying white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/51\">",
"     51",
"    </a>",
"    ] and, in some cases, minor signal hypointensity of the putamina and pallida, while the signal in the rest of the basal ganglia remains normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/57\">",
"     57",
"    </a>",
"    ]. Voxel-based morphometry using MRI has shown atrophy predominantly involving the frontal lobes, basal ganglia, and brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H168534604\">",
"     'Potential biomarkers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of striatal dopamine transporter imaging (DaTscan) in CBD and other parkinsonian syndromes is discussed separately. (See",
"    <a class=\"local\" href=\"#H168534604\">",
"     'Potential biomarkers'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of Parkinson disease\", section on 'DaTscan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428740482\">",
"    <span class=\"h2\">",
"     Electrophysiologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic tests in CBD are not diagnostic but can provide helpful information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electroencephalography (EEG), normal at first, might show latent asymmetric slowing. Later in the course of the disease, EEG may show slowing in the delta and theta frequency, with occasional sharp waves that enhance with activation procedures such as hyperventilation and photic driving [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/59\">",
"       59",
"      </a>",
"      ]. Myoclonic jerks, present in approximately 50 percent of patients with CBD, show no preceding spike or sharp waves on back-averaged EEG testing [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electromyography might help to characterize the myoclonus of CBD, demonstrating the ultra short-latency, stimulus-sensitive myoclonus typical of the disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/26\">",
"       26",
"      </a>",
"      ]. Although myoclonus can have many causes, the myoclonic activity seen in CBD is action or reflex-induced rather than spontaneous [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/39\">",
"       39",
"      </a>",
"      ]. Electromyography reveals the short duration (25 to 50 msec) muscle discharges of simultaneously activated antagonist muscle pairs, occurring in clusters [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Somatosensory evoked potentials, generally abnormal in CBD, rarely show enlargement of potentials and do not correlate with the presence of myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link&amp;anchor=H9#H9\">",
"     \"Symptomatic (secondary) myoclonus\", section on 'Corticobasal degeneration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168533548\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the diagnostic uncertainty in life, the post-mortem examination is necessary to make a definitive diagnosis of CBD. From the initial description of neuropathology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/2\">",
"     2",
"    </a>",
"    ], CBD was considered mainly as a distinct neurodegenerative disorder characterized by asymmetric frontoparietal atrophy with extensive neuronal loss, gliosis, and ballooned achromatic (ie, without staining) neurons. The descriptive pathologic terms &ldquo;ballooned neurons&rdquo; and &ldquo;neuronal achromasia&rdquo; eventually became synonymous with the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15\">",
"     15",
"    </a>",
"    ]. Today, a broader range of pathology has been established, and the overlap of many features with other neurodegenerative disorders such as frontotemporal dementia (including Pick disease), Alzheimer disease and progressive supranuclear palsy (PSP) is increasingly recognized to be related to a shared tau-related cytoskeletal pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,11,60\">",
"     4,11,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical autopsy findings in CBD on gross examination include an asymmetric frontoparietal cortical atrophy that is oftentimes localized to the perirolandic region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,11,61\">",
"     4,11,61",
"    </a>",
"    ]. A study comparing neuropathology between cases of CBD (n = 9) and PSP (n = 24) showed that gross brain atrophy was detectable in CBD irrespective of whether first symptoms were motor or cognitive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/61\">",
"     61",
"    </a>",
"    ]. Brain atrophy was progressive and, in contrast to PSP, was similar to that seen in other frontotemporal dementia tauopathies. There is also depigmentation and degeneration of the substantia nigra [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On microscopic examination, the cortex shows loss of neurons and gliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,9,11,15,62\">",
"     4,9,11,15,62",
"    </a>",
"    ]. The deeper layers of the involved cortex show achromatic ballooned neurons that are comprised of neurofilaments, with eccentrically located nuclei and almost complete loss of Nissl substance. Subcortical nuclei are affected variably, but the pars compacta of the substantia nigra usually shows uniformly severe loss of neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11\">",
"     11",
"    </a>",
"    ]. Neurofibrillary tangles are found variably in the neurons of the cortex, striatum, globus pallidus, subthalamic nucleus, and brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11\">",
"     11",
"    </a>",
"    ], but are absent in the hippocampus, occipital cortex, and inferior and medial temporal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15\">",
"     15",
"    </a>",
"    ]. The distribution of subcortical neurofibrillary tangles in CBD is similar to that seen in PSP, but the strands have a more thread-like appearance in CBD, rather than the globose appearance typical of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11\">",
"     11",
"    </a>",
"    ]. Tau-positive astrocytic plaques are presently considered highly suggestive of CBD, as are tau inclusions in the glia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. These same astrocytic plaques, however, are reported in cases of PSP as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/11,63\">",
"     11,63",
"    </a>",
"    ]. Tau-positive glial pathology and ballooned neurons have additionally been reported in Pick's disease and PSP, but are considered diagnostic of CBD in the absence of numerous Pick bodies and globose neurofibrillary tangles [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/60\">",
"     60",
"    </a>",
"    ]. Neuropil threads and basophilic inclusions are present in the substantia nigra and basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormally configured tau protein is a common neuropathological feature of CBD and PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although CBD and PSP are considered sporadic disorders, both are associated with a greater frequency of homozygosity for the H1 tau haplotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Tau-associated pathology shows up predominantly in the corpus callosum and parasagittal and paracentral gyri in CBD, as contrasted with PSP, where these findings are concentrated in subcortical regions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/61\">",
"     61",
"    </a>",
"    ]. In CBD, the tau histopathology correlates with areas of cortical atrophy.",
"   </p>",
"   <p>",
"    Tau is a protein that is expressed mainly in neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/66\">",
"     66",
"    </a>",
"    ]. It is involved in axonal transport and stabilization of neuronal microtubules. Abnormal phosphorylation of tau interferes with microtubule function, impairs axonal transport, and leads to tau aggregation into neurofibrillary tangles. Normal brain tau contains six isoforms that are generated by alternative messenger RNA splicing of a single tau gene on chromosome 17. Alternative splicing of exon 10 results in isoforms with either three-repeats (3R) or four-repeats (4R) of the tau microtubule binding domain. The normal ratio of 3R-tau and 4R-tau is approximately equal; disruption of the normal ratio is thought to lead to neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/66\">",
"     66",
"    </a>",
"    ]. Isoforms common to both CBD and PSP are aggregates of the 4R-tau that occur because of splicing of exon 10. In contrast, the 3R-tau form dominates in the aggregates of some other tau disorders, such as Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uniqueness of CBD pathology and its distinction as a separate disease came into question with the advances in molecular biology demonstrating a link to the tau haplotype H1 that is associated with tau protein pathology in PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/8\">",
"     8",
"    </a>",
"    ]. As illustrated above, findings once thought unique to CBD have been increasingly recognized in other neurodegenerative disorders that display tau-associated pathology, particularly PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/4,11,60\">",
"     4,11,60",
"    </a>",
"    ]. These findings have led some experts to suggest that these two entities, expressed clinically as different phenotypes, are actually the same disease, or at least genetically linked. However, while both PSP and CBD are more frequently associated with homozygosity for the H1 tau haplotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], the H1 haplotype is also more common in patients with Parkinson disease compared with controls, even though tau accumulation and aggregation are not a part of its pathological picture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/67\">",
"     67",
"    </a>",
"    ], except in the late stages when dementia often occurs and Alzheimer pathology is present in a significant minority of autopsied brains [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/68\">",
"     68",
"    </a>",
"    ]. Therefore, the significance of the shared genetic associations among these disorders is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100657484\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of corticobasal syndrome (CBS) is made clinically, relying on the history and neurologic examination (see",
"    <a class=\"local\" href=\"#H7743087\">",
"     'Diagnostic criteria'",
"    </a>",
"    below). Neuropathologic determination remains the gold standard for definitive diagnosis of corticobasal degeneration (CBD) (see",
"    <a class=\"local\" href=\"#H168533548\">",
"     'Pathology and pathophysiology'",
"    </a>",
"    above). The clinical diagnosis of CBS is challenging because of the wide variety of presentations, which include early behavioral or cognitive impairment in addition to the classic asymmetric akinetic-rigid motor syndrome.",
"   </p>",
"   <p>",
"    There are no established biologic markers for the disease. Routine blood, urine, and cerebrospinal fluid examinations are all unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15,16,48\">",
"     15,16,48",
"    </a>",
"    ]. Structural and functional imaging studies can be employed but none is considered sensitive enough to reliably distinguish CBD from other atypical parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/16,69,70\">",
"     16,69,70",
"    </a>",
"    ]. Structural brain imaging may be most helpful when done serially at 6 to 12 month intervals, as abnormalities become apparent over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15\">",
"     15",
"    </a>",
"    ]. Tests of olfaction can be a useful diagnostic tool, since olfactory dysfunction (hyposmia or anosmia) is common in Parkinson disease, rare in CBD and progressive supranuclear palsy, and is mildly impaired in multiple system atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnosis of Parkinson disease\", section on 'Olfactory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the hallmarks of the CBD is poor or no responsiveness to levodopa therapy, a feature that is sometimes employed as a diagnostic screening tool for patients with suspected CBD who have prominent motor symptoms. The response to levodopa therapy can be tested using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    up to",
"    <span class=\"nowrap\">",
"     25/250",
"    </span>",
"    mg administered three times a day for at least two months. The response to levodopa is considered poor if the extrapyramidal features do not show marked improvement, or if the therapeutic effect is transient (ie, lasts less than a year). An excellent response to dopaminergic therapy is an important supportive feature for establishing the diagnosis of Parkinson disease, as discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of Parkinson disease\", section on 'Response to dopaminergic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450881492\">",
"    <span class=\"h2\">",
"     Antemortem versus postmortem diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of corticobasal syndrome (CBS) does not reliably predict the neuropathologic diagnosis of corticobasal degeneration (CBD). The challenge of making the correct antemortem diagnosis of CBD is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 40 patients with a clinical diagnosis of CBS, the final autopsy diagnoses were CBD (35 percent), Alzheimer disease (23 percent), progressive supranuclear palsy (13 percent), frontotemporal lobar degeneration with TDP-43 inclusions (13 percent), mixed pathology (13 percent), Pick disease (3 percent), and multiple system tauopathy without argyrophilia (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found that the clinical diagnosis of CBS made by neurologists who were unaware of the neuropathologic diagnosis had a low sensitivity (35 percent) but a high specificity (&gt;99 percent) for pathologically proven CBD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 21 cases with an antemortem clinical diagnosis of CBS, only 5 (23 percent) had pathologic confirmation of the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/7\">",
"       7",
"      </a>",
"      ]. Conversely, among 19 cases with a pathologic diagnosis of CBD, a correct antemortem clinical diagnosis was made in 5 (26 percent).",
"     </li>",
"     <li>",
"      In a study of 19 cases of pathologically confirmed CBD from the UK brain bank, five had been diagnosed correctly in life, yielding a sensitivity of 26 percent, and four of these had received an alternative earlier diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/7\">",
"       7",
"      </a>",
"      ]. Eight were diagnosed with progressive supranuclear palsy (PSP). Of 21 cases with a clinical diagnosis of CBS, only 5 had CBD pathology, giving a positive predictive value of 24 percent. Six others had PSP. Forty-two percent of CBD cases presented clinically with a progressive supranuclear palsy phenotype and 29 percent of cases had PSP pathology. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that the phenotype of CBS is nonspecific with respect to the underlying neuropathology, and that CBD is often misdiagnosed during life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22,71\">",
"     22,71",
"    </a>",
"    ]. However, for most of the studies cited above, the experience of the practitioners who made the clinical diagnosis of CBS is uncertain. Unlike studies of Parkinson disease, the accuracy of movement disorder specialist diagnoses in atypical parkinsonism has not been well-studied. Thus, the generally poor performance for the antemortem diagnosis of",
"    <span class=\"nowrap\">",
"     CBS/CBD",
"    </span>",
"    revealed in the available data may relate to inadequate recognition of the clinical features and the lack of truly discriminating clinical criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743087\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proposed clinical and research criteria for CBD have been published but have not been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/16,72-74\">",
"     16,72-74",
"    </a>",
"    ]. The criteria are meant to help differentiate CBD from Parkinson disease and other atypical parkinsonian syndromes. However, these criteria are",
"    <strong>",
"     not",
"    </strong>",
"    helpful for differentiating CBD with dementia as a presenting feature from other neurodegenerative dementias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic criteria proposed in 2003 for CBD include the following core features [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insidious onset and progressive course",
"     </li>",
"     <li>",
"      No identifiable cause (eg, tumour, infarct)",
"     </li>",
"     <li>",
"      Cortical dysfunction with at least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal or asymmetric ideomotor apraxia",
"     </li>",
"     <li>",
"      Alien limb phenomena",
"     </li>",
"     <li>",
"      Cortical sensory loss",
"     </li>",
"     <li>",
"      Visual or sensory hemineglect",
"     </li>",
"     <li>",
"      Constructional apraxia",
"     </li>",
"     <li>",
"      Focal or asymmetric myoclonus",
"     </li>",
"     <li>",
"      Apraxia of speech or nonfluent aphasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrapyramidal dysfunction as reflected by at least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal or asymmetric appendicular rigidity unresponsive to levodopa",
"     </li>",
"     <li>",
"      Focal or asymmetric appendicular dystonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive findings from investigations are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variable degrees of focal or lateralized cognitive dysfunction, with relative preservation of learning and memory on neuropsychometric testing",
"     </li>",
"     <li>",
"      Focal or asymmetric atrophy on imaging with CT or MRI, typically maximal in parieto-frontal cortex",
"     </li>",
"     <li>",
"      Focal or asymmetric hypoperfusion on single photon emission computed tomography and positron emission tomography, typically maximal in parieto-frontal cortex, with or without involvement of basal ganglia or thalamus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proposed pathologic criteria for the diagnosis of CBD require the detection of characteristic tau-immunoreactive lesions in the neurons, glia, and cell processes of the cortex and striatum (caudate and putamen), particularly astrocytic plaques and thread-like lesions in both white matter and gray matter, in conjunction with neuronal loss in focal cortical regions and in the substantia nigra [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/75\">",
"     75",
"    </a>",
"    ]. Supportive features include ballooned cortical neurons, cortical atrophy, and tau-positive oligodendroglial coiled bodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168534604\">",
"    <span class=\"h2\">",
"     Potential biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established biomarkers for the diagnosis of CBD. Functional imaging studies cannot reliably distinguish CBD from other atypical parkinsonian syndromes.",
"   </p>",
"   <p>",
"    The positron emission tomography (PET) finding most typical of CBD is asymmetric cerebral glucose hypometabolism most prominent in the posterior frontal, inferior parietal, and superior temporal regions, thalamus, and striatum of the affected hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/58,70,76,77\">",
"     58,70,76,77",
"    </a>",
"    ]. There is also an asymmetric decrease in global cortical oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DaTscan, ie, striatal dopamine transporter imaging using 123I-FP-CIT single photon emission computed tomography (SPECT), is generally abnormal in CBD in a manner similar to Parkinson disease. Compared with patients who had Parkinson disease, one study reported that FP-CIT binding reduction in patients with CBD was characterized by increased variability, more uniform reduction throughout the striatum, and greater hemispheric asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/79\">",
"     79",
"    </a>",
"    ]. However, this test cannot be used to definitively differentiate CBS from other atypical parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of Parkinson disease\", section on 'DaTscan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SPECT scanning using 99mTc-hexamethylpropylene amine oxime (HMPAO) shows regional reductions in HMPAO uptake in the medial frontal, temporoparietal, superior parietal, and the lateral frontal regions of both hemispheres [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/81\">",
"     81",
"    </a>",
"    ]. In addition, there is bilateral and symmetric reduction in thalamic blood flow in patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/81\">",
"     81",
"    </a>",
"    ]. These results demonstrated a greater reduction in cerebral cortical blood flow and more asymmetry than those patients with idiopathic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of PET and SPECT imaging is generally limited to research centers.",
"   </p>",
"   <p>",
"    Analysis of brain atrophy by MRI voxel-based morphometry is another method that may be useful to differentiate the underlying pathology of patients who present clinically with CBS. In a case-control study of 24 patients diagnosed on clinical grounds with CBS who had MRI during life and came to autopsy, a neuropathologic diagnosis of CBD was made in 7, Alzheimer disease in 6, progressive supranuclear palsy in 6, and frontotemporal lobe degeneration in 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/82\">",
"     82",
"    </a>",
"    ]. Focal atrophy detected on MRI by voxel-based morphometry in premotor and supplemental motor areas was suggestive of CBD or progressive supranuclear palsy, while more widespread atrophy was suggestive of frontotemporal lobe degeneration or Alzheimer disease. A subsequent study evaluated 18 patients with an autopsy diagnosis of CBD and 40 patients with known histopathology who presented with clinical CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"     22",
"    </a>",
"    ]. Anterior spread of atrophy from the perirolandic regions suggested that the underlying pathology was CBD, while brainstem and subcortical atrophy was more likely with progressive supranuclear palsy pathology, and posterior spread to temporoparietal cortex was more likely with Alzheimer pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743108\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticobasal degeneration is most often misdiagnosed as either idiopathic Parkinson disease, progressive supranuclear palsy, or multiple system atrophy (predominant parkinsonism subtype) when presenting primarily with motor symptoms (",
"    <a class=\"graphic graphic_table graphicRef75519 \" href=\"UTD.htm?7/55/8060\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79095 \" href=\"UTD.htm?16/7/16509\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of Parkinson disease\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain disorders associated with a predominant dementia, including Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia, Pick disease, and progressive supranuclear palsy, can present rarely with focal myoclonus, apraxia, alien limb phenomena, focal or hemidystonia, or rigidity, making them difficult to distinguish from CBD with dementia. While some studies suggest that Alzheimer disease and CBD presenting as CBS can be differentiated by clinical features, neuropsychological testing, and imaging, the ability to make a correct diagnosis in life remains difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients presenting with a rapid progression of symptoms suggesting CBD with dementia as a feature should be evaluated for a prion disease, such as Creutzfeldt-Jakob disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168533973\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of 14 patients with autopsy-proven CBD, median survival from onset of symptoms was approximately 8 years (range 2.5 to 12.5 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"     12",
"    </a>",
"    ]. The most common cause of death is from complications of immobility or dysphagia, such as pneumonia and sepsis. In another series of 15 patients with autopsy-proven CBD, the mean disease duration was 5.4 years (range 2 to 8 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7743115\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no neuroprotective treatments for CBD and no medications that provide significant symptomatic benefits as seen with levodopa in idiopathic Parkinson disease. Treatment remains targeted at symptom amelioration and at best is not wholly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/84\">",
"     84",
"    </a>",
"    ]. Palliative and safety measures provide relatively little relief of symptoms but are important in overall management of the multiple stresses experienced by patient and caregiver",
"   </p>",
"   <p>",
"    One of the hallmarks of CBD is poor responsiveness to levodopa, which can be used as a diagnostic screening tool (see",
"    <a class=\"local\" href=\"#H100657484\">",
"     'Diagnosis'",
"    </a>",
"    above). Thus, the main role of levodopa in patients with suspected CBD is diagnostic; a poor or unsustained response to levodopa therapy is generally observed in patients with CBD and can help to distinguish it from idiopathic Parkinson disease. In addition, levodopa therapy may provide some degree of transient benefit for parkinsonism, which is commonly present in CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/85\">",
"     85",
"    </a>",
"    ]. However, this benefit is modest and is seen in only a minority of patients with CBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/17\">",
"     17",
"    </a>",
"    ]. At times the effect is demonstrated more clearly upon withdrawal of the drug. Alternative agents for parkinsonism, such as the dopamine receptor agonists, the MAO-B inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    and dopamine releasing agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , give an even less consistent response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications that can be used for management of tremor include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    and anticholinergics may be useful for rigidity and dystonia, and clonazepam is helpful in some cases for myoclonus. Botulinum toxin has been reported to provide some relief of dystonic spasms and pain in the limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/15,17,48\">",
"     15,17,48",
"    </a>",
"    ]. Unfortunately, the efficacy of these treatment agents is low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/14/5354/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients should be weaned off any pharmacologic agent that proves to be ineffective, as side effects are frequent. Dopaminergic drugs should not be abruptly stopped.",
"   </p>",
"   <p>",
"    Depression is common and should be recognized early so that appropriate treatment can be implemented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with cognitive dysfunction, it is reasonable to prescribe a cholinesterase inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Walking devices should be utilized for assistance in preventing falls, although upper limb apraxia may make their use impossible, and a wheelchair should be employed when balance is affected to the point of falling. Occupational therapy can be beneficial in assisting with devices for eating and grooming and other adaptive measures. Physical therapy may help some patients with dysfunction of balance and gait as well as range of motion and positioning of dystonic limbs. Orthotic splinting may also reduce contractures and relieve pressure from tightly clinched fingers pressing into the palm.",
"   </p>",
"   <p>",
"    Diet and nutrition are important aspects of care, especially because dysphagia is a common late symptom. Consultations from a dietician and a speech therapist can help manage both the risk of malnutrition and aspiration.",
"   </p>",
"   <p>",
"    The care required for a patient with CBD can be very taxing for the family. Attention should be given to cues that the family is in distress and referrals for respite care, in-home health assistance, hospice, and counseling should be made. Treatment is aimed at safety, symptom management, and patient and family supportive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428740953\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticobasal degeneration (CBD) was originally described as an asymmetric, akinetic-rigid neurodegenerative syndrome with cerebral cortical dysfunction. It is now recognized that pathologically proven CBD often begins as a cognitive or behavioral disturbance. Because the cognitive and motor features considered characteristic of CBD are not specific to CBD, some experts to the use the term &ldquo;corticobasal syndrome&rdquo; for cases with a clinical diagnosis, while reserving &ldquo;corticobasal degeneration&rdquo; for cases with neuropathologic confirmation. (See",
"      <a class=\"local\" href=\"#H7743066\">",
"       'Historical aspects and nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated annual incidence of CBD ranges from 0.62 to 0.92 per 100,000 population, with an estimated prevalence of approximately 5 to 7 per 100,000 population. The disease typically presents in the sixth to eighth decades of life with onset of symptoms occurring at a mean age of 61 to 63 years. (See",
"      <a class=\"local\" href=\"#H7743073\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic description of CBD is that of a progressive asymmetric movement disorder with symptoms initially affecting one limb, including various combinations of akinesia and extreme rigidity, dystonia, focal myoclonus, ideomotor apraxia, and alien limb phenomenon (",
"      <a class=\"graphic graphic_table graphicRef55825 \" href=\"UTD.htm?34/5/34908\">",
"       table 1",
"      </a>",
"      ). Cognitive impairment is a common manifestation of CBD and may be a presenting feature, while the parkinsonian motor features may emerge later as the disease progresses. Important cognitive features of CBD include executive dysfunction, aphasia, apraxia, behavioral change, and visuospatial dysfunction, with relatively preserved episodic memory. (See",
"      <a class=\"local\" href=\"#H7743080\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In early stages of CBD, brain imaging with CT and MRI may be normal [44]. As the disease progresses, abnormalities in the form of asymmetric cortical atrophy are observed in up to half of patients. Focal atrophy predominantly involves the posterior frontal and parietal regions, along with dilatation of the lateral ventricles. (See",
"      <a class=\"local\" href=\"#H168532478\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologically, CBD is characterized by asymmetric frontoparietal atrophy with extensive neuronal loss, gliosis, and ballooned, achromatic neurons. Subcortical nuclei are affected variably, but the pars compacta of the substantia nigra usually shows uniformly severe loss of neurons. Neurofibrillary tangles are found in the neurons of the cortex, striatum, globus pallidus, subthalamic nucleus, and brainstem. The distribution of neurofibrillary tangles in CBD is similar to that seen in progressive supranuclear palsy, but the strands have a more thread-like appearance in CBD rather than the globose appearance typical of progressive supranuclear palsy. A fundamental abnormality of the cytoskeletal protein tau is the underlying pathologic substrate of CBD. Tau-positive astrocytic plaques are considered highly suggestive of CBD, as are tau inclusions in the glia. (See",
"      <a class=\"local\" href=\"#H168533548\">",
"       'Pathology and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CBD is made clinically. However, the diagnosis is often difficult because of the wide variety of presentations reported for CBD, which may include predominant cognitive impairment rather than the classic asymmetric akinetic-rigid syndrome. There are no established biological markers for the disease. Neuropathologic determination remains the gold standard for definitive diagnosis. CBD is most often misdiagnosed as either idiopathic Parkinson disease, progressive supranuclear palsy, or multiple systems atrophy when presenting primarily with motor symptoms (",
"      <a class=\"graphic graphic_table graphicRef75519 \" href=\"UTD.htm?7/55/8060\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79095 \" href=\"UTD.htm?16/7/16509\">",
"       table 3",
"      </a>",
"      ). A poor or unsustained response to levodopa therapy is generally observed in patients with CBD and can help to distinguish it from idiopathic Parkinson disease. Certain disorders associated with predominant dementia, particularly Alzheimer disease, dementia with Lewy bodies, and frontotemporal dementia (including Pick disease), can present rarely with focal myoclonus, apraxia, alien limb phenomena, and rigidity, making them difficult to distinguish from CBD with dementia. (See",
"      <a class=\"local\" href=\"#H100657484\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The median survival with CBD from onset of symptoms is approximately eight years or less. (See",
"      <a class=\"local\" href=\"#H168533973\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no neuroprotective treatments for CBD and no medications that provide significant symptomatic benefits. Treatment remains targeted at symptom amelioration but is not consistently effective. (See",
"      <a class=\"local\" href=\"#H7743115\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although a poor or unsustained response to levodopa is generally observed in patients with CBD, levodopa therapy may provide some degree of modest transient benefit for parkinsonism in a minority of patients with CBD. The response can be tested using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"       carbidopa-levodopa",
"      </a>",
"      up to",
"      <span class=\"nowrap\">",
"       25/250",
"      </span>",
"      mg administered three times a day for at least two months. The response is considered poor if the extrapyramidal features do not show marked improvement, or if the therapeutic effect is transient (ie, lasts less than a year). With little response, the drug should be tapered off gradually. (See",
"      <a class=\"local\" href=\"#H7743115\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/1\">",
"      Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/2\">",
"      Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/3\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1985. A 66-year-old man with progressive neurologic deterioration. N Engl J Med 1985; 313:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/4\">",
"      Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999; 53:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/5\">",
"      Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 ( Pt 5):1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/6\">",
"      Shelley BP, Hodges JR, Kipps CM, et al. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009; 24:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/7\">",
"      Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/8\">",
"      Di Maria E, Tabaton M, Vigo T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000; 47:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/9\">",
"      Scaravilli T, Tolosa E, Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Mov Disord 2005; 20 Suppl 12:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/10\">",
"      Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol 2000; 82:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/11\">",
"      Schneider JA, Watts RL, Gearing M, et al. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997; 48:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/12\">",
"      Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/13\">",
"      Murray R, Neumann M, Forman MS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/14\">",
"      DePold Hohler A, Ransom BR, Chun MR, et al. The youngest reported case of corticobasal degeneration. Parkinsonism Relat Disord 2003; 10:47.",
"     </a>",
"    </li>",
"    <li>",
"     Watts R, Mirra SS, Richardson EP. Corticobasal ganglionic degeneration. In: Movement disorders, Marsden CD, Fahn S (Eds), Butterworth-Heinemann, Oxford 1994. p.282.",
"    </li>",
"    <li>",
"     Stover NP, Wainer BH, Watts RL. Corticobasal degeneration. In: Movement Disorders: Neurologic Principles &amp; Practice, 2nd ed, Watts RL, Koller WC (Eds), McGraw-Hill, New York 2004. p.763.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/17\">",
"      Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/18\">",
"      Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/19\">",
"      Hassan A, Whitwell JL, Boeve BF, et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 2010; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/20\">",
"      Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/21\">",
"      Bergeron C, Davis A, Lang AE. Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol 1998; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/22\">",
"      Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/23\">",
"      Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/24\">",
"      Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117 ( Pt 5):1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/25\">",
"      Greene PE, Fahn S, Lang AE, et al. What is it? Case 1, 1990: progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. Mov Disord 1990; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     Kumar R, Bergeron C, Pollanen M, Lang AE. Corticobasal degeneration. In: Parkinson's Disease and Movement Disorders, 3rd ed, Jankovic J, Tolosa E.  (Eds), Lippincott Williams &amp; Wilkins, Baltimore 1998. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/27\">",
"      Ahlskog JE. Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Parkinsonism Relat Disord 2000; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/28\">",
"      Litvan I, Grimes DA, Lang AE. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Adv Neurol 2000; 82:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/29\">",
"      M&uuml;ller J, Seppi K, Stefanova N, et al. Freezing of gait in postmortem-confirmed atypical parkinsonism. Mov Disord 2002; 17:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/30\">",
"      Factor SA, Higgins DS, Qian J. Primary progressive freezing gait: a syndrome with many causes. Neurology 2006; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/31\">",
"      Thompson PD, Shibasaki H. Myoclonus in corticobasal degeneration and other neurodegenerations. Adv Neurol 2000; 82:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/32\">",
"      Carella F, Ciano C, Panzica F, Scaioli V. Myoclonus in corticobasal degeneration. Mov Disord 1997; 12:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/33\">",
"      Frattali CM, Sonies BC. Speech and swallowing disturbances in corticobasal degeneration. Adv Neurol 2000; 82:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/34\">",
"      Rivaud-P&eacute;choux S, Vidailhet M, Gallouedec G, et al. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/35\">",
"      Vidailhet M, Rivaud-P&eacute;choux S. Eye movement disorders in corticobasal degeneration. Adv Neurol 2000; 82:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/36\">",
"      Stover NP, Watts RL. Corticobasal degeneration. Semin Neurol 2001; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/37\">",
"      Rottach KG, Riley DE, DiScenna AO, et al. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 1996; 39:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/38\">",
"      Zadikoff C, Lang AE. Apraxia in movement disorders. Brain 2005; 128:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/39\">",
"      Leiguarda R, Merello M, Balej J. Apraxia in corticobasal degeneration. Adv Neurol 2000; 82:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/40\">",
"      Huey ED, Pardini M, Cavanagh A, et al. Association of ideomotor apraxia with frontal gray matter volume loss in corticobasal syndrome. Arch Neurol 2009; 66:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/41\">",
"      Hanna PA, Doody RS. Alien limb sign. Adv Neurol 2000; 82:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/42\">",
"      Litvan I, Agid Y, Goetz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 1997; 48:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/43\">",
"      Barclay CL, Bergeron C, Lang AE. Arm levitation in progressive supranuclear palsy. Neurology 1999; 52:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/44\">",
"      Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology 2003; 61:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/45\">",
"      McMonagle P, Blair M, Kertesz A. Corticobasal degeneration and progressive aphasia. Neurology 2006; 67:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/46\">",
"      Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008; 21:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/47\">",
"      Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/48\">",
"      Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol 2004; 3:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/49\">",
"      Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology 1996; 46:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/50\">",
"      Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995; 45:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/51\">",
"      Soliveri P, Monza D, Paridi D, et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999; 53:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/52\">",
"      Geda YE, Boeve BF, Negash S, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/53\">",
"      Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/54\">",
"      O'Keeffe FM, Murray B, Coen RF, et al. Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy. Brain 2007; 130:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/55\">",
"      Gim&eacute;nez-Rold&aacute;n S, Mateo D, Benito C, et al. Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. J Neural Transm Suppl 1994; 42:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/56\">",
"      Hauser RA, Murtaugh FR, Akhter K, et al. Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging 1996; 6:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/57\">",
"      Savoiardo M, Grisoli M, Girotti F. Magnetic resonance imaging in CBD, related atypical parkinsonian disorders, and dementias. Adv Neurol 2000; 82:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/58\">",
"      Yamauchi H, Fukuyama H, Nagahama Y, et al. Atrophy of the corpus callosum, cortical hypometabolism, and cognitive impairment in corticobasal degeneration. Arch Neurol 1998; 55:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/59\">",
"      Vion-Dury J, Rochefort N, Michotey P, et al. Proton magnetic resonance neurospectroscopy and EEG cartography in corticobasal degeneration: correlations with neuropsychological signs. J Neurol Neurosurg Psychiatry 2004; 75:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/60\">",
"      Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996; 55:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/61\">",
"      Schofield EC, Caine D, Kril JJ, et al. Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Mov Disord 2005; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/62\">",
"      Dickson DW, Yen SH, Suzuki KI, et al. Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol 1986; 71:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/63\">",
"      Nishimura T, Ikeda K, Akiyama H, et al. Immunohistochemical investigation of tau-positive structures in the cerebral cortex of patients with progressive supranuclear palsy. Neurosci Lett 1995; 201:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/64\">",
"      Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/65\">",
"      Higgins JJ, Golbe LI, De Biase A, et al. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000; 55:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/66\">",
"      Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 2008; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/67\">",
"      Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 2007; 62:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/68\">",
"      Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/69\">",
"      Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/70\">",
"      Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/71\">",
"      Reich SG, Grill SE. Corticobasal degeneration. Curr Treat Options Neurol 2009; 11:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/72\">",
"      Riley DE, Lang AE. Clinical diagnostic criteria. Adv Neurol 2000; 82:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/73\">",
"      Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 Suppl 5:S15.",
"     </a>",
"    </li>",
"    <li>",
"     Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Neurodegenerative diseases, Calne DB (Ed), WB Saunders, Philadelphia 1994. p.877.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/75\">",
"      Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/76\">",
"      Coulier IM, de Vries JJ, Leenders KL. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord 2003; 18:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/77\">",
"      Brooks DJ. Functional imaging studies in corticobasal degeneration. Adv Neurol 2000; 82:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/78\">",
"      Nagahama Y, Fukuyama H, Turjanski N, et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997; 12:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/79\">",
"      Cilia R, Rossi C, Frosini D, et al. Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS One 2011; 6:e18301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/80\">",
"      K&auml;gi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/81\">",
"      Kreisler A, Defebvre L, Lecouffe P, et al. Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis. Mov Disord 2005; 20:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/82\">",
"      Whitwell JL, Jack CR Jr, Boeve BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/83\">",
"      Hu WT, Rippon GW, Boeve BF, et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord 2009; 24:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/84\">",
"      Karakaya T, Fu&szlig;er F, Prvulovic D, Hampel H. Treatment options for tauopathies. Curr Treat Options Neurol 2012; 14:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/14/5354/abstract/85\">",
"      Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007; 22:2141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14135 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5354=[""].join("\n");
var outline_f5_14_5354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H428740953\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100657524\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7743066\">",
"      HISTORICAL ASPECTS AND NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7743073\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7743080\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172630660\">",
"      Motor and gait involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172641960\">",
"      Speech alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172641856\">",
"      Oculomotor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168534479\">",
"      Cortical dysfunction and apraxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172631425\">",
"      - Alien limb phenomenon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85747391\">",
"      - Aphasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168534501\">",
"      - Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85747116\">",
"      Behavioral change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168532478\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H428740482\">",
"      Electrophysiologic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168533548\">",
"      PATHOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100657484\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450881492\">",
"      Antemortem versus postmortem diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7743087\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168534604\">",
"      Potential biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7743108\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168533973\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7743115\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428740953\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14135|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/5/34908\" title=\"table 1\">",
"      Clinical manifestations of CBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/55/8060\" title=\"table 2\">",
"      Differential diagnosis of CBD by motor signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/7/16509\" title=\"table 3\">",
"      Diagnostic algorithm of parkinsonism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=related_link\">",
"      Multiple system atrophy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=related_link\">",
"      Progressive supranuclear palsy (PSP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_14_5355="Causes of acute symptomatic seizures";
var content_f5_14_5355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of provoked epileptic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Alcohol &amp; drug withdrawal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug intoxication",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyponatremia, Hypernatremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypomagnesium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypocalcemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypoglycemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nonketotic hyperglycemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypoxia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperthyroidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dialysis disequilibrium syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Porphyria",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5355=[""].join("\n");
var outline_f5_14_5355=null;
var title_f5_14_5356="Classification of VWD";
var content_f5_14_5356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of von willebrand disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Inheritance",
"      </td>",
"      <td class=\"subtitle1\">",
"       VWF activity",
"      </td>",
"      <td class=\"subtitle1\">",
"       RIPA",
"      </td>",
"      <td class=\"subtitle1\">",
"       Multimer pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Type 1 (partial quantitative deficiency)",
"      </td>",
"      <td>",
"       Autosomal dominant",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Uniform decrease; all multimers present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"       Type 2 (qualitative variant)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Type 2A",
"      </td>",
"      <td>",
"       Autosomal dominant or recessive",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Decreased large multimers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Type 2B",
"      </td>",
"      <td>",
"       Autosomal dominant",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Increased",
"      </td>",
"      <td>",
"       Decreased large multimers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Type 2M",
"      </td>",
"      <td>",
"       Autosomal dominant or recessive",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Decreased",
"      </td>",
"      <td>",
"       Uniform decrease; all multimers present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Type 2N",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Type 3 (severe)",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Markedly decreased or absent",
"      </td>",
"      <td>",
"       Markedly decreased or absent",
"      </td>",
"      <td>",
"       Undetectable; usually cannot visualize",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VWF activity: ristocetin cofactor; RIPA: Ristocetin-induced platelet aggregation.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5356=[""].join("\n");
var outline_f5_14_5356=null;
var title_f5_14_5357="Causes weight loss and FTT";
var content_f5_14_5357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical causes of weight loss and failure to thrive in the elderly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"8\">",
"       Malignancy",
"      </td>",
"      <td>",
"       Lung",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hematologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastrointestinal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genitourinary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prostate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatobiliary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"8\">",
"       Gastrointestinal",
"      </td>",
"      <td>",
"       Peptic ulcer disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dysmotility syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial overgrowth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mesenteric ischemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory bowel disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celiac disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Cardiac",
"      </td>",
"      <td>",
"       Heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coronary artery disease, unstable angina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Pulmonary",
"      </td>",
"      <td>",
"       Chronic obstructive pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bronchiectasis-chronic infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Infectious",
"      </td>",
"      <td>",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subacute bacterial endocarditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent bladder infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent aspiration pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Neurologic",
"      </td>",
"      <td>",
"       Dementia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stroke",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Motor neuron disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"5\">",
"       Endocrine",
"      </td>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adrenal insufficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperparathyroidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperthyroidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypothyroidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Deficiency states",
"      </td>",
"      <td>",
"       Thiamine deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitamin B12 deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitamin C deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Zinc deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Renal",
"      </td>",
"      <td>",
"       Uremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nephrotic syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"4\">",
"       Psychiatric",
"      </td>",
"      <td>",
"       Depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bereavement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mania/psychosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Rheumatic",
"      </td>",
"      <td>",
"       Polymyalgia rheumatica/giant cell arteritis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Rehman, H. Involuntary Weight Loss in the Elderly. Clinical Geriatrics 2005; 13:37. Copyright &copy; 2005 American Geriatrics Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5357=[""].join("\n");
var outline_f5_14_5357=null;
var title_f5_14_5358="Partial airway collapse";
var content_f5_14_5358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Partial airway collapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Model of counterbalancing forces that influence airway patency",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Thach, B. Neuromuscular control of the upper airway. In: Beckerman, R, Brouillette, R, Hunt, C (Eds), Respiratory Control Disorders in Infants and Children, Baltimore, Williams &amp; Wilkins, 1990, p. 47.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5358=[""].join("\n");
var outline_f5_14_5358=null;
var title_f5_14_5359="Pleural fluid venous pressure";
var content_f5_14_5359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Pleural fluid formation with increased systemic venous pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of pleural fluid formation with increased venous pressure. An elevation in systemic venous pressure both increases filtration from the parietal pleural microvessels (the intercostal arteries, solid arrows) and decreases lymphatic drainage into the venous system (dashed open&nbsp;arrow). Filtration from visceral pleural microvessels (the bronchial arteries) is unaffected (dashed solid arrows).&nbsp;In comparison, an elevation in pulmonary venous pressure would&nbsp;increase filtration from the visceral pleural microvessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_14_5359=[""].join("\n");
var outline_f5_14_5359=null;
